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SUMMARY 
 
The development of modulated drug delivery vehicles with remarkable efficacy in 
recent years has prompted the design of smart polymeric systems that are responsive to 
external stimuli or changes in the physiological environment. Therefore, two novel 
polymer systems, such as cholesteryl end-capped poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide) [P(NIPAAm-co-DMAAm)] and poly(N-isopropylacrylamide-co-
N,N-dimethylacrylamide-co-oleic acid) [P(NIPAAm-co-DMAAm-co-OA)] that are 
thermally and/or pH responsive were employed to fabricate core-shell nanoparticles 
for targeted drug delivery. Two hydrophobic drugs with different molecular structures, 
such as cyclosporin A (CyA) and indomethacin (IMC), were chosen as model drugs.  
 
The blank and drug-loaded core-shell nanoparticles were characterised using various 
analytical tools. Transmission electron microscopy and dynamic light scattering 
measurements revealed that the core-shell nanoparticles were spherical, and had a 
mean diameter less than 200 nm. P(NIPAAm-co-DMAAm-co-OA) nanoparticles 
demonstrated a change in particle size with respect of pH. The critical association 
concentration (CAC) of cholesteryl end-capped P(NIPAAm-co-DMAAm) and 
P(NIPAAm-co-DMAAm-co-OA)  polymers in ultra pure water was estimated as 20.0 
and 64.0 mg/L, respectively. The CAC value of cholesteryl end-capped P(NIPAAm-
co-DMAAm) polymer was reduced to 12.0 mg/L in phosphate buffer saline (PBS), 
while the CAC of P(NIPAAm-co-DMAAm-co-OA)  polymer remained unchanged in 
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The lower critical solution temperature (LCST) of cholesteryl end-capped P(NIPAAm-
co-DMAAm) and P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles in water 
was estimated to be 37.0oC and 32.8oC, respectively. However, the presence of salts in 
PBS, as well as serum proteins in bovine serum albumin (BSA) and fetal bovine serum 
(FBS), reduced the LCST of both core-shell nanoparticles systems. The LCST of 
P(NIPAAm-co-DMAAm-co-OA) polymer was increased with increasing pH. The 
core-shell nanoparticles demonstrated reversibility of thermoresponsive aggregation 
and dispersion. Meanwhile, it was also demonstrated that P(NIPAAm-co-DMAAm-co-
OA) core-shell nanoparticles experienced deformation and reformation of structure in 
heating and cooling thermal cycles through the LCST.  
 
Loading of drug molecules was a complicated process. Various factors that influence 
drug encapsulation efficiency, such as fabrication temperature, pH, initial drug loading, 
structure and size of drug molecules, as well as polymer concentration were 
investigated. Better entrapment was yielded for CyA compared to IMC because of its 
lower dissolution loss during the fabrication process. Higher drug encapsulation 
efficiency was obtained at lower fabrication temperatures and pH, but at higher 
polymer concentrations. However, drug precipitation, which was caused by rapid 
solvent removal at high temperatures, was the dominant factor that influenced the drug 
encapsulation efficiency.  
 
In vitro release of drug-loaded core-shell nanoparticles was studied at different 
temperatures, pH and drug loading level. Cholesteryl end-capped P(NIPAAm-co-
DMAAm) and P(NIPAAm-co-DMAAm-co-OA)  core-shell nanoparticles showed 
higher CyA release at temperatures below the LCST than above the LCST. 
 Summary 
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P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles also demonstrated pH 
responsive release of CyA and IMC, wherein higher release was obtained at higher pH. 
Furthermore, an increase in drug loading level resulted in a slower release of IMC.  
 
Hence, the core-shell nanoparticles developed would make a good carrier for targeted 
drug delivery because they possess a great potential for passive targeting due to their 
small size, low CAC and good stability against serum proteins, as well as active 
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CHAPTER 1 INTRODUCTION 
 
Drug delivery is rapidly becoming an integral part of drug development strategies 
within the pharmaceutical and biotechnology industries. Global drug delivery market 
is currently valued at US$50 billion a year, or 12.5% of world total pharmaceutical 
sales. However, it has been estimated that by the year of 2005, the sales of drug 
delivery products will reach US$100 billion, as technologies currently being 
researched and developed reach fruition and are commercialised (Informa 
Pharmaceuticals, 2000). 
 
Until the early 1970s, drugs were delivered to the human body exclusively via oral and 
injection means. In the case of oral doses, the drug concentration in blood first rises 
rapidly to a maximum level, and then falls gradually as the drug is metabolised. On the 
other hand, intravenous injection results in an exponential decrease from the maximum 
blood concentration (Kaneko et al., 1998). Often the initial maximum concentration is 
above the therapeutically desirable level, increasing the risk of side effects. Conversely, 
the minimum concentration may be below the therapeutically effective level, hence 
repeated administration becomes necessary [Figure 1.1 (a)].  
 
Conventional drug therapy generally involves the periodic dosing of a therapeutic 
agent that has been formulated in a way to ensure its stability, activity, and 
bioavailability. For most drugs, conventional methods of formulation are quite 
effective. However, some drugs are unstable and toxic, and have a narrow therapeutic 
range, or exhibit extreme solubility problems. Sometimes, they require localisation to a 
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problems in conventional drug therapy have prompted the development of controlled 
drug delivery system to keep drug concentrations in effective ranges for longer periods 
by a single dose and to deliver drugs only to target sites [Figure 1.1 (b)].  
 
  
Figure 1.1 Drug levels in the blood with (a) traditional drug dosing and (b) controlled-
delivery dosing (Brannon-Peppas, 1997) 
 
The earliest drug delivery systems, first introduced in the 1970s by Yolles and 
coworkers, were based on polymers formed from lactic acid. Since then, much 
progress has been made on the design of efficient drug carriers such as liposomes 
(Lasic, 1996; Tardi et al., 1986; Weinstein, 1987), microparticles (Alonso, 1996; 
Brannon-Peppas, 1995) and nanoparticles (Cavallaro et al., 1994; Niwa et al., 1995), 
but many of these delivery vehicles have shown limited therapeutic efficacy in the 
clinic (Duncan, 1992). The use of liposomes is restricted because they are structurally 
fragile, and taken up easily by monophagocytes in various tissues of the 
reticuloendothelial system (RES) (Allen, 1988) and have a low loading efficiency of 
hydrophobic drugs (Kabanov et al., 1992). On the other hand, microparticles (1 to 
5000 µm) are too large to direct the drugs to target tissues across the mucosal 
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To overcome these problems, polymeric nanoparticles are proposed as an alternative 
drug carrier. Due to their small size, nanoparticles may be useful as sustained-release 
injections for the delivery of drugs to a specific organ or target site. However, since 
most drugs are relatively hydrophobic, conjugation of drugs with polymeric 
nanoparticles formed from homopolymer, statistical copolymer or natural polymer 
often leads to precipitation because of a high local concentration of hydrophobic drug 
molecules bound along the polymer chain. Polymeric core-shell nanoparticles can 
solve these problems associated with the conventional polymeric nanoparticles due to 
their unique properties (Harada and Kataoka, 1998; Yokoyama et al., 1990; Yokoyama 
et al., 1994b). 
 
Polymeric core-shell nanoparticles, a colloidal drug delivery system, can be easily 
fabricated, and their chemical as well as physical properties can be readily controlled 
via molecular synthesis. Besides, they can also protect the drugs having short in vivo 
half-lives, and improve the bioavailability of drugs having poor aqueous solubility. 
The drug in the carrier is unchanged, therefore its absorption, distribution, metabolism 
and excretion after being released from the carrier is similar to that of the native drug. 
Moreover, its biological efficiency when released from the carrier is the same as that 
when used alone. In addition, polymeric core-shell nanoparticles can be localised to a 
desired site, reducing systemic toxicity, and this localisation can increase the drug 
potency. 
 
In recent years, controlled drug delivery formulations and the polymers used in these 
systems have become much more sophisticated, with the ability to do more than 
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been developed to respond to changes in the biological environment, and thus alter the 
drug-release process accordingly. The release of the drug may be constant or cyclic 
over a long period, or it may be triggered by the environment or other external stimuli 
such as pH (General and Thünemann, 2001; Govender et al., 2001; Kang and Bae, 
2001; Leroux et al., 1996; Leroux et al., 2001), electricity (Eisenberg and Grodzinsky, 
1984; Kwon et al., 1991), temperature (Chung et al., 1998; Huang et al., 1994; Kim et 
al., 2000a; Kohori et al., 1998; Meyer et al., 2001), ultrasound (Husseini et al., 2002; 
Marin et al., 2001) and electrochemicals (Takeoka et al., 1995) (Brannon-Peppas, 
1997). Stimuli-sensitive drug carriers are more advantageous in some cases. For 
instance, during the 1980s, diabetes, which requires fluctuating levels of insulin to 
mimic the natural biofeedback mechanism, became a widely investigated “test case” 
for the application of a modulated release system (Sinko and Kohn, 1993).  
 
Therefore, the design of stimuli-sensitive core-shell nanoparticles that are able to 
selectively recognise their physiological objective is of great interest. These core-shell 
nanoparticles are expected to present a double targeting character, which are the 
passive targeting resulting from both their small size and highly hydrated shell 
structure, and active physical affinity targeting resulting from their stimuli-responsive 
properties. 
 
In the next chapter, a review of the research work done in polymeric core-shell 
nanoparticles as drug carriers will be presented. An understanding of this will then 
bring into focusing the objectives of this project. Chapter 3 describes the methodology 
of this research project while the results obtained are presented and discussed in 
Chapter 4. The conclusions and recommendations will be in Chapter 5. 
 
 Literature Review 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 Introduction to polymeric core-shell nanoparticles 
 
Polymeric core-shell nanoparticles are known to exhibit micellar behaviour (Kwon et 
al., 1995; Kwon et al., 1993a; Bahadur et al., 1988) and were first proposed as drug 
carriers by Bader et al. (1984). They have emerged as potential drug carriers for poorly 
soluble drugs because they mimic aspects of natural carriers, such as viruses and serum 
lipoproteins, in terms of structure and function. Table 2.1 lists various polymeric core-
shell nanoparticle systems developed recently. Core-shell nanoparticles as drug 
carriers are able to provide a number of advantages. They can solubilise hydrophobic 
drugs and thus increase their bioavailability by protecting the drugs from possible non-
specific tissue adsorption and inactivation under the effect of biological surroundings. 
They also offer attractive characteristics, particularly a small size, which is in the range 
of 10-200 nm that allows them to stay in the body (in the blood) long enough to 
provide gradual accumulation in the required area and body regions with leaky 
vasculature. Furthermore, this size range allows for easy sterilisation because the 
nanoparticles can easily pass through the 0.22 to 0.45 µm filters commonly used for 
filtration sterilisation (Yokoyama, 1998). Additionally, these core-shell nanoparticles 
can be targeted using stimuli-responsive polymers or attaching specific ligands to the 
outer surface.  
 
Polymeric core-shell nanoparticles consist of two phases, which are the inner core 
phase and the outer shell phase. Each phase plays a different role and the functions 
required for drug delivery systems can be shared by these structurally separated phases. 
 
 Literature Review 
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Table 2.1 Core-shell nanoparticles used for drug delivery 
Types of 
system 





PEG-P(Asp) ADR Yokoyama et al., 1993; 
Yokoyama et al., 1998b  
 PHPMA DOX Ulbrich et al., 2003 
 PEO-b-P(HAZA) Amphotericin B Adam and Kwon, 2003 
 Acetal-PEG-PDLLA Charged 
peptides 
Yamamoto et al., 1999; 
Yamamoto et al., 2001 
 PEO-b-PHAA MTX Yu and Kwon, 1999 
 PEO-b-PHEA MTX Yu and Kwon, 2000 
 PLGA-PEG DOX Yoo et al., 2002; Yoo and 
Park, 2001 
 PEO-P(Asp) ADR Yokoyama et al., 1994a; 
Kwon et al., 1994a 





ADR Chung et al., 1999; Chung et 
al., 2000 
 PEG-P(Asp) ADR and ADR 
dimer 
Fukushima et al., 1999 
 PEO-PBLA ADR Kwon et al., 1995 
 PEO-b-PHSA Amphotericin B Lavasanifar et al., 2000; 
Lavasanifar et al., 2002b; 
Lavasanifar et al., 2001a 
 Pluronic DOX Marin et al., 2002 
 CA/PNIPAAm IMC Kim et al., 2000c 
 PLA/ PNIPAAm IMC Kim et al., 2000b 
 PEG-PBLA DOX Kataoka et al., 2000 
 PEG-PBLA KRN  Yokoyama et al., 1998a 
 PEG-DSPE Protein Weissig et al., 1998 
 MePEG/є-CL IMC Shin et al., 1998 
 P(NIPAAm-co-MAA-
co-ODA) 
AlClPc Taillefer et al., 2000  
 PBLG/PEO CZ Jeong et al., 1998 
 PA/SDM ADR Na et al., 2003 
 PEG-P(Asp) Cisplatin Yokoyama et al., 1996 





Govender et al., 2001 
 PLL-g-PLGA Plasmid DNA Jeong and Park, 2002 
 PEG-P(Asp) Lysozyme Harada and Kataoka, 2001; 
Harada and Kataoka, 1998; 
Harada and Kataoka, 1999 
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As shown in Figure 2.1, the nanoparticles core serves as a microreservoir for the 
incorporation of hydrophobic drugs and they are also responsible for pharmacological 
activities through drug loading and release. On the other hand, the outer shell is 
responsible for core-shell nanoparticles stabilisation of the interface between the 
hydrophobic core of the nanoparticles and the external environment; and also 
interactions with the biocomponents such as proteins and cells. These interactions 
determine pharmacokinetic behaviour and biodistribution of drugs. Therefore, in vivo 
delivery of drugs may be controlled by the outer shell segment independently of the 










Figure 2.1 The concept and functionality of a core-shell nanoparticle as a drug carrier 
(Adapted from Yokoyama, 1998) 
 
2.2 Amphiphilic copolymers 
 
Polymeric core-shell nanoparticles represent a different class of micelles and are 
formed from copolymers containing both hydrophilic and hydrophobic monomer units. 
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hydrophilic segment surrounds the core as a hydrated outer shell. There are several 
classifications of polymers, as presented in Figure 2.2. Unlike homopolymer made of 
identical monomeric units, copolymers are formed from two types of monomeric units 
differing in their solubility. Following polymerisation, these monomeric units can be 
organised into a polymeric chain in different positions depending on the type of 
copolymer desired, such as random, block and graft copolymers. 
 
Homopolymer 
(Does not form core-shell nanoparticles) 
AAAAAAAAAAAAA 
Random Copolymer ABAAABABBABBBA 






A: hydrophilic       B: hydrophobic 
AAAAAAAAAAAAAA 
   B                    B   
   B                    B 
   B                    B 
   B 
Figure 2.2 A schematic presentation of different polymers which can be created 
depending on the number of types of repeat units; homopolymer (one type), copolymer 
(two or more types) (Adapted from Torchilin, 2001) 
 
The copolymer materials used in the preparation of drug carriers are often block 
copolymers, comprising a block or sequence of one repeat unit coupled to a block of 
another repeat unit (Cowie, 1994). This can be observed from the rapid development of 
research on core-shell nanoparticles made from block copolymers as shown in Figure 
2.3. The advantage of using block copolymers over random copolymer materials is the 
much narrower total molecular weight and sequence distributions for block 
copolymers (Cowie, 1994; Wilczek-Vera, 1996). The versatility afforded by the use of 
copolymers is largely due to the easily controlled of the material properties, such as 
copolymer ratio, molecular weight, molecular weight distribution and block 
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composition. Therefore, polymeric core-shell nanoparticles can be tailor-made to suit a 
particular application through careful manipulation of the properties of the copolymer 











Figure 2.3 Development of work on ( ) block copolymer-drug conjugates and ( ) block 
copolymer core-shell nanoparticles for non-covalently incorporated drugs (Kabanov 
and Alakhov, 2000) 
  
Some polymers may exhibit a stimuli-responsive character, wherein small changes in 
pH (Katayama and Ohata, 1985; Kim et al., 1994; Liu et al., 2002; Kyriakides et al., 
2002; Serres et al., 1996; Taillefer et al., 2000 ; Ulbrich et al., 2003), temperature 
(Christova et al., 2003; Eekman et al., 2003; Feil et al., 1993; Kim et al., 1994; Serres 
et al., 1996; Urry, 1997), metabolites (Cartier et al., 1995), or the application of an 
ultrasound (Husseini et al., 2000; Marin et al., 2002; Rapoport et al., 1999), pressure 
(Tanaka et al., 1998), or light (Gerasimov et al., 1999; Suzuki and Tanaka, 1990) can 
cause sharp changes in the polymer volume and shape reversibly (Mikos et al., 1993).  
 
For examples, chemical signals, such as pH, metabolites and ionic factors will change 
the molecular interactions between the polymer chains or between polymer chain and 
Year 
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solutes present in the system. On the other hand, physical stimuli such as temperature 
or electrical potential may provide various energy sources for molecular motions and 
altering molecular interactions. These interactions will change the properties of the 
polymer materials, such as swelling, solubility, configuration or conformation change, 
redox states and crystalline/amorphous transition (Audus, 1991; Junginger, 1992; Park, 
1997).  
 
Hence, due to the potential applications of such polymers in the normal physiological 
process, many research groups have been developing drug delivery systems based on 
these responsive polymers in the last few decades. Among them, the most commonly 
studied polymers having environmental sensitivity are either pH or temperature 
sensitive. 
 
2.2.1 Temperature-responsive polymers 
 
Poly(N-isopropylacrylamide) (PNIPAAm) and its copolymers are the most frequently 
studied temperature-sensitive polymers (Dhara and Chatterji, 2000). It exhibits a lower 
critical solution temperature (LCST) of around 32°C in water. The polymer has a 
deceptively simple structure with a hydrophobic backbone, containing a strong 
hydrophilic amide group (–CONH2) substituted with a hydrophobic isopropyl group. 
The isopropyl group tends to pull away from the water molecules, while the amide 
group prefers to be in water because of its strong hydrogen-bonding capacity with 
water molecules. It is generally believed that this hydrophilic-hydrophobic push-pull is 
responsible for the LCST behaviour of PNIPAAm in water (Dhara and Chatterji, 2000).  
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At low temperatures (below the LCST), the polymer has a good solubility in water due 
to its strong hydrogen bonding between the hydrophilic groups and water, which 
outweighs the unfavourable free energy correlated to the exposure of hydrophobic 
groups to water. Then, as the temperatures increase, the hydrophobic interactions 
between hydrophobic side groups become more intense as the hydrogen bonding 
weakens. Above the LCST, interactions between hydrophobic groups become 
dominant, leading to an entropy-driven polymer collapse and phase separation (Figure 
2.4). The decreased motional freedom of the polymer chain is compensated by an 
increase in entropy due to the release of structured water around the hydrophobic 








Figure 2.4 Structural changes occurring when the solution temperature is cycled 
through the LCST of PNIPAAm core-shell nanoparticles  
(Adapted from Chung et al., 1998) 
 
2.2.2 pH-responsive polymers 
 
The variation in pH along the gastrointestinal tract (Evans et al., 1988) and also the 
small but clear difference in pH between tumours and normal tissues (about 7.0 in 
tumours and 7.4 in normal tissues) (Van den Berg et al., 1982) has motivated many 
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been performed on polymers containing weakly acidic or basic groups in the polymeric 
backbone. For instance, while anionic pH-sensitive polymers contain the carboxylic 
(Benrebouh et al., 2001; Chiu et al., 2001) and sulfonate or sulfate groups (Kathmann 
et al., 1997), primary or tertiary amine monomers (Sakata et al., 2001; Yuk et al., 1997) 
have been used as typical groups in cationic copolymers.  
 
The charge density of the polymers depends on the pH and ionic composition of the 
outer solution to which the polymer is exposed. Altering the pH of the solution will 
cause swelling or deswelling of the crosslinked polymer matrices (Figure 2.5). 
Polyacidic polymer matrices will be swollen at high pH, because the acidic groups will 
be deprotonated and hence ionised. The opposite holds for polybasic polymer matrices, 







Figure 2.5 A schematic presentation of pH controlled drug delivery systems. Small 
dots represent drugs; lines represent polymer chains (∆ can be positive or negative) 
(Kost, 1999) 
 
Based on the unique properties of pH and temperature-sensitive polymers, researchers 
have used them as a hydrophilic block, and built them into a hydrophobic polymer 
backbone to form amphiphilic block copolymers. The nanoparticles made from the 
stimuli-sensitive block copolymers can be employed to achieve both passive and active 
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2.3 Preparation of core-shell nanoparticles 
 
Basically, there are two methods for the preparation of core-shell nanoparticles, which 
are the direct dissolution method and the dialysis method, as illustrated in Figure 2.6. 
The choice of a method mostly depends on the solubility of the copolymer used in 
water. For instance, if the copolymer is marginally soluble in water, the direct 
dissolution method is employed, whereas if the copolymer is poorly water-soluble, the 
dialysis method is preferred (Kim et al., 2000a, Yokoyama et al., 1998a, Shin et al., 
1998, Cammas et al., 1997, Ha et al., 1999, Lavasanifar et al., 2001b). 
 
The direct dissolution method merely involves the addition of copolymer into water or 
other aqueous medium such as phosphate buffer saline (PBS) (Kabanov et al., 1995). 
In the case of dialysis method, the copolymer is first dissolved in an organic solvent 
that is miscible with water, such as N,N-dimethylformamide (DMF) (Fukushima et al., 
1999; Lavasanifar et al., 2001a; Kwon et al., 1995; Kim et al., 1998; Yokoyama et al., 
1998a), tetrahydrofuran (THF) (Kim et al., 1998), N,N-dimethylsulfoxide (DMSO) 
(Jeong and Park, 2002; Lavasanifar et al., 2002b; Yokoyama et al., 1998a), N,N-
dimethylacetamide (DMAc) (Allen et al., 1999b; Chung et al., 2000; Kim et al., 1998; 
Lavasanifar et al., 2000; Yamamoto et al., 2002) and N-ethylacetamide (Chung et al., 
1999; Chung et al., 2000;). The copolymer-solvent mixture is stirred, and then dialysed 
against water. During the dialysis, the organic solvent is removed, and the core-shell 
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Figure 2.6 A schematic presentation of the direct dissolution and dialysis methods 
employed for the preparation of polymeric core-shell nanoparticles 
 
2.4 Drug incorporation 
 
Hydrophobic drugs can be incorporated into polymeric core-shell nanoparticles by 
chemical conjugation (Kataoka, 1994; Yoo et al., 2002) or physical entrapment 
(Kataoka et al., 1993; Kwon and Okano, 1996; Kwon and Okano, 1999; La et al., 
1996). However, in some cases, incorporation of the hydrophobic drug has been 
employed using both chemical conjugation and physical entrapment. For instance, 
Yokoyama et al. (1998b) found that the physical entrapment of adriamycin was higher 
in micelles formed from adriamycin-conjugated poly(ethylene glycol)-b-poly(aspartic 
acid) [PEG-b-P(Asp)] than in micelles formed from the PEG-b-P(Asp) copolymer 
alone. 
 
If a drug is chemically attached to the hydrophobic block of the copolymer, its 
incorporation into the inner core proceeds simultaneously with the formation of 
Dissolve 
Copolymer in 
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nanoparticles. However, different protocols are used for physical drug incorporation, 
depending on the method for the preparation of core-shell nanoparticles (Figure 2.6). 
For example, in the direct dissolution method, copolymer solution in water is added to 
a drug, which is dried from an organic solvent, or alternatively the drug in an organic 
solvent, which is immiscible with water (e.g. chloroform), is added to the water 
solution of preformed nanoparticles. The entrapment of the drug is achieved with 
solvent evaporation (Kataoka et al., 2000; Kwon et al., 1997). For the dialysis method, 
the drug is dissolved together with the copolymer in an organic solvent. In some cases, 
the oil-in-water emulsion dialysis method is also used for the incorporation of 
hydrophilic drugs into nanoparticles (Kwon and Okano, 1996).  
 
Chemical conjugation of hydrophobic drugs requires a covalent bond, such as an 
amide bond, between the specific groups of the drug and the hydrophobic block of the 
copolymer. Therefore, physical encapsulation of drugs within the polymeric core-shell 
nanoparticles is generally a more attractive approach than polymer-drug conjugates 
since many drug molecules do not bear reactive functional groups (e.g. carboxyl, 
hydroxyl or amino groups) for chemical conjugation, and the free functional site is 
sometimes required for the pharmacological effectiveness of the drug. In addition, 
conjugates of drugs may show distinctly different biological properties relative to the 
parent drugs. This can cause inherent difficulties in characterisation and regulatory 
approval even for already approved drugs (Lavasanifar et al, 2002a). 
 
However, there are some drawbacks for physical encapsulation of drugs, including low 
encapsulation capacity and rapid release of encapsulated drugs (i.e. dose dumping). 
Alternatively, attaching the drugs to the core-forming block allows for greater drug 
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loading efficiency and amount within the core of the nanoparticles (Yoo and Park; 
2001). In addition, drug conjugation increases the stability of drugs. For example, the 
PLGA-b-PEG micelles containing chemically conjugated doxorubicin showed a more 
sustained release profile of doxorubicin over a longer period, and were more 
effectively transported within cells by endocytosis compared to those containing non-
conjugated doxorubicin (Yoo and Park; 2001).  
 
Furthermore, core-shell nanoparticles formed from the conjugate are rather stable in 
vivo, and their disintegration takes hours. This is attributed to the covalent bonds, 
which are resistant to enzymatic cleavage mainly because of the steric hindrance, and 
cannot be readily hydrolysed (Duncan and Kopechek, 1984; Ulbrich et al., 1987). It 
was reported that upon intravenous injection, there was an increased circulation time in 
the blood for the conjugates of doxorubicin with PEG-b-P(Asp) copolymer compared 
to non-conjugated doxorubicin (Kwon et al., 1993b). In another study, PEG-b-P(Asp)  
micelles containing only chemically conjugated doxorubicin were found to have no 
anti-tumour activity, which is attributed to the slow release of free drug from the 
micelles (Yokoyama et al., 1998b). 
 
2.5 Loading capacity 
 
The factors that influence the extent of incorporation of drugs into the core-shell 
nanoparticles have been extensively investigated. One of the important factors is the 
compatibility between the drug and the core-forming block. This compatibility is based 
on drug characteristics such as molecular volume, interfacial tension against water, 
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polarity, hydrophobicity, charge and degree of ionisation (Allen et al., 1999a; 
Nagarajan et al., 1986). 
 
Aside from polymer-drug compatibility, the length of the core-forming and shell-
forming blocks can also play an important role in loading capacity. Increasing the 
length of hydrophobic block has been found to provide a larger core size per 
nanoparticle and thus greater ability to entrap hydrophobic drugs (Gadelle et al., 1995). 
On the other hand, a significant increase in the length of the hydrophilic block 
decreases the aggregation number, leading to a decrease in the degree of solubilisation 
since there is only a small hydrophobic volume for drug incorporation (Xing and 
Mattice, 1997). 
 
There is also evidence that polymer and drug concentration can affect drug 
solubilisation. Xing and Mattice (1997) reported that an increase in the polymer 
concentration increased the solubilisation capacity of drug to the saturation level. This 
phenomenon can be explained from the hydrophobic interactions between the drug and 
the core-forming block. Stronger interactions can be achieved with more core-forming 
blocks. Similarly, the presence of a hydrophobic drug can enhance the aggregation of 
amphiphilic copolymer molecules, and thus lower the critical association concentration 
(CAC). This further leads to an increased number of core-shell nanoparticles present in 
the solution (Gadelle et al., 1995; Xing and Mattice, 1997), and provides more 
hydrophobic cores for drug incorporation. Increasing the drug concentration was 
reported to produce larger nanoparticles, which in turn increased the solubilisation 
capacity of nanoparticles (Xing and Mattice, 1997). 
 
 
 Literature Review 
 
 - 18 - 
2.6 Formation of core-shell nanoparticles 
 
The self-association process of amphiphilic copolymers is similar to that of low 
molecular weight surfactants. At very low concentrations, the polymers only exist as 
single chain and have a strong tendency to be adsorbed at the air-water interface. An 
increase in amphiphile concentration leads to the decrease of the surface tension, 
which will then become constant as the polymer concentration reach a critical 
association concentration (CAC), evidencing the saturation of the interface with 
amphiphile molecules and core-shell nanoparticles formation in the bulk phase 







Figure 2.7 Self-assembly and disassembly of core-shell nanoparticles at 
concentrations above/below the CAC (Adapted from Chung et al., 1998) 
 
At the CAC, a significant amount of solvent can be found inside the hydrophobic core 
and the core-shell nanoparticles are described as loose aggregates. Further increase in 
polymer concentration allows core-shell nanoparticles to be in a low-energy 
configuration, and the remaining solvent is slowly released from the hydrophobic core, 
resulting in a decrease in the size of nanoparticles (Jones and Leroux, 1999). 
 
Core-shell nanoparticles are formed as a result of two forces. One is an attractive force 
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unlimited growth of the core-shell nanoparticles to a distinct macroscopic phase 
(Astafieva et al., 1993; Price, 1983).  
 
The driving force for self-association of amphiphilic copolymers is the inner-core 
cohesive interactions such as hydrophobic, electrostatic and π-π interactions, as well as 
hydrogen bonding (Yokoyama, 1998). Hydrophobic interactions are probably the most 
common driving force for the incorporation of hydrophobic drugs (Kim et al., 1999; 
La et al., 1996; Na et al., 2000). On the other hand, the electrostatic interaction may be 
applied to macromolecules with electric charges in high density such as DNA and 
RNA, because of their anionic phosphodiester bonds existing in each repeating unit, 
and may also be applied to highly charged proteins such as aspartic acid and lysine 
residues (Berti et al., 2000; Harada and Kataoka, 1998; Katayose and Kataoka, 1996; 
Kataoka et al., 1996; Seymour et al., 1998). Hydrogen bonding and π-π interactions 
may work in association with other cohesive interactions. For example, drugs with 
aromatic rings are incorporated into the nanoparticles based on π-π and hydrophobic 
interactions (Kataoka et al., 2000; Kwon et al., 1993b). Table 2.2 lists various cohesive 
interactions for incorporation of corresponding drugs. 
 
Table 2.2 Cohesive interactions for formation of core-shell nanoparticles and drug 
incorporation (Adapted from Yokoyama, 1998) 







DNA, RNA, highly charged proteins 
Proteins 
Aromatic ring-rich drugs 
Cisplatin (interchain cross-link) 
 * Two or more interactions may occur simultaneously. 
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Generally, core-shell nanoparticles can be formed using two types of amphiphilic 
copolymers in which the hydrophobic chain is either randomly bound to the 
hydrophilic polymer or grafted to one end of the hydrophilic polymer. Core-shell 
nanoparticles fabricated from the randomly modified polymer are smaller than the end-
modified polymer. The particle size is mainly determined by the hydrophobic forces 
that sequester the hydrophobic chains in the core. The excluded volume repulsion 
between the hydrophobic chains limits their size (Winnik et al., 1992).  
 
When terminal hydrophobic groups associate to form core-shell nanoparticles, the 
water clusters immobilised around the hydrophobic segments are excluded from the 
core. Nonetheless, there is no direct interaction between the core and the hydrophilic 
shell, which remains as mobile linear chains in the core-shell nanoparticle structure 
(Chung et al., 1998; Winnik et al., 1992). On the other hand, randomly modified 
polymers associate in such a way that the hydrophobic and hydrophilic parts of the 
polymer are entangled together, allowing possible contact between the core and the 
aqueous media. In this case, the hydrophilic chains forming the shell are less mobile 
(Chung et al., 1998). 
 
2.7 Stability of core-shell nanoparticles 
 
Polymeric core-shell nanoparticles possess high structural stability provided by 
entanglement of polymer chains in the inner core. However, the nanoparticles should 
be stable just enough to provide a sufficient time for drug delivery and accumulation in 
the target region, and simultaneously be able to slowly dissociate into single chains to 
provide their easy and problem-free elimination from the body (Torchilin, 2001). 
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Stability of core-shell nanoparticles both in vitro and in vivo, as well as their clearance 
from the body depends on the critical association concentration (CAC) values.  
 
The stability of core-shell nanoparticles consists of two different aspects: 
thermodynamic stability and kinetic stability (Lavasanifar et al., 2002a). A core-shell 
nanoparticle is thermodynamically stable relative to disassembly to single chains in 
pure water if the total copolymer concentration is above the CAC. However, even if a 
nanoparticle system is below its CAC, it may still be kinetically stable and survive at 
least for a certain period of time, if the core is large and the core is in a glassy state or 
if it is crystalline and thus physically crosslinked. Table 2.3 shows factors influencing 
the stability of core-shell nanoparticles as a drug delivery vehicle. 
 
Table 2.3 Factors influencing the thermodynamic or kinetic stability of core-shell 
nanoparticles (Allen et al., 1999a) 

















Kwon et al., 1994b; Kwon and 









Alexandridis et al, 1994; Creutz et 








Yokoyama et al., 1998b 
 
2.7.1 Thermodynamic stability 
 
Thermodynamic stability is described by an equilibrium constant between a single 
polymer chain and the core-shell nanoparticles structure, or more conveniently called 
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the CAC. In general, polymeric core-shell nanoparticles have much smaller CAC 
values than that of micelles forming from low molecular weight surfactants. 
 
The CAC value is determined by many factors, including the nature and length of the 
core-forming block, length of the hydrophilic block and the presence of hydrophobic 
solubilisates. However, the nature and length of the core-forming block have the 
greatest effect on the CAC. Amphiphilic polymers, containing a highly hydrophobic 
block have lower CAC values in water than those having less hydrophobic blocks. 
Large molecular dimensions of the core-forming segment in the polymers induce a 
strong tendency for aggregation, thus this pushes the CAC to a very small level 
(Kataoka, 1994; Kwon et al., 1993a). For instance, the CAC values for poly(styrene)-
b-poly(ethylene oxide) (PS-b-PEO) copolymers, containing highly hydrophobic 
polystyrene block ranged between 1 and 5 ppm (Wilhelm et al., 1991). 
 
A delivery system is subject to ‘sink conditions’ or severe dilution upon intravenous 
injection into an animal or human subject. Therefore, core-shell nanoparticles with 
high CAC may not be suitable as drug targeting carriers since they are unstable in an 
aqueous environment and easily dissociate upon dilution. In some cases, injecting a 
larger volume or a more concentrated nanoparticle solution would prevent the 
copolymer concentration from falling below the CAC immediately upon injection 
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2.7.2 Kinetic stability 
 
Kinetic stability is described by low dissociation rates of core-shell nanoparticles 
above/below the CAC and may be more important than the thermodynamic stability in 
physiological environments where metabolism and excretion take place, and 
interactions with biological components (e.g. cells, proteins, and lipids) exist, which 
can destroy core-shell nanoparticles structure. Yokoyama et al. (1993) reported that 
PEO-P(Asp/DOX) micelles had a very low rate of dissociation in water and PBS, but 
the dissociation was accelerated in presence of serum. 
 
The rate of disassembly depends upon the physical state of the hydrophobic core. The 
copolymers are unable to dissociate freely from polymeric core-shell nanoparticles 
with solid-like core, e.g. those with high glass transition temperatures (Kwon and 
Okano, 1996). Therefore, core-shell nanoparticles formed from copolymers containing 
a hydrophobic block, which has a high glass transition temperature, tend to 
disassemble more slowly than those with a low glass transition temperature. The 
polymeric nanoparticles with poly(styrene) core (Prochaska et al., 1992; Wang et al., 
1992) are a good example. Since the core is likely in a glassy state at room temperature, 
the nanoparticles are unable to dissociate into single chains for exchange between 
core-shell nanoparticles at room temperature (Wang et al., 1992). 
 
The rate of disassembly is also influenced by the same factors that affect the rate of 
unimers exchange between the nanoparticles, such as solvent inside the core, the 
hydrophobic content of the copolymer and the lengths of both hydrophobic and 
hydrophilic blocks. For example, Creutz et al. (1998) discovered that for micelles 
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formed from poly((dimethylamino)alkyl methacrylate-b-sodium methacrylate), the rate 
of unimers exchange decreased with an increase in the hydrophobic/hydrophilic 
balance of the copolymer.  
  
Moreover, the incorporation of hydrophobic compounds into the core-shell 
nanoparticles may enhance the stability of nanoparticles. Yokoyama et al. (1998b) 
reported that both physical entrapment and chemical conjugation of adriamycin (ADR) 
into the micelle core increased the structural stability of PEG-b-P(Asp) micelles. They 
suggested that the presence of both physically entrapped drug and chemically 
conjugated drug increased the hydrophobic interactions within the core, producing 
micelles that were more tightly packed. 
 
2.8 Drug release kinetics 
 
The release of drug from polymeric core-shell nanoparticles depends upon the rate of 
drug diffusion from the nanoparticles, the stability of nanoparticles and the rate of 
polymer biodegradation. If the nanoparticles are stable and the rate of biodegradation 
of the copolymer is slow or non-biodegradable, drug release rate is mainly influenced 
by the strength of interactions between the drug and the core-forming block (La et al.; 
1996), the physical state of the inner core (Kwon et al., 1997), the amount of drug 
loaded (Kim et al., 1998), the molecular volume of the drug, the length of the core-
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2.8.1 Polymer-drug interactions 
 
Strong polymer-drug interactions can enhance drug loading and hinder drug release 
from the nanoparticles. Therefore, a compromise must be achieved such that both the 
loading level and the release kinetics of the drug are optimised. Conditions that 
weaken the hydrophobic-hydrophobic interactions between the drug and the 
nanoparticles core can accelerate the drug release rate. La et al. (1996) found that the 
release of indomethacin from poly(ethylene oxide)-poly(β-benzyl L-aspartate) micelles 
was greatly enhanced when the pH value of the external medium was changed from 
1.2 to 7.4 at 37oC. At a pH value below the pKa (4.5) of indomethacin, indomethacin in 
the nanoparticles remained unionised with little tendency for release. As the pH value 
of the medium was increased, more of the carboxylic acid groups in the polymer and 
the carboxylic acid group in indomethacin became ionised, and the hydrophobic-
hydrophobic interactions that held indomethacin within the poly(β-benzyl L-aspartate) 
core weakened, resulting in faster indomethacin release. 
 
In the case of drug conjugates, the drug is only released when the covalent bond 
between the drug and the polymer has cleaved. Water penetration and hydrolysis of the 
liable bonds in the nanoparticles core (bulk erosion), followed by drug diffusion may 
occur in relatively hydrophilic liquid-like core structures. However, for rigid core 
structure, drug release is dependent on the rate of nanoparticles dissociation since 
water diffusion into hydrophobic core is restricted (Lavasanifar et al., 2002a). The 
slow dissociation of nanoparticles into single polymeric chains and further hydrolysis 
of the liable bonds may result in a sustained drug release (Li and Kwon, 2000). The 
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drug release may be delayed until the carrier reaches the target sites, if the 
nanoparticles structure is sufficiently stable. 
 
2.8.2 Drug localisation 
 
The incorporated drug may lie within the hydrophobic core or shell itself, or at the 
interface between the core and shell. The localisation of the drug depends on its 
physical properties and the interactions between the drug and core/shell-forming 
blocks (Hruska et al., 1993; Teng et al., 1998). Less hydrophobic drugs are localised in 
the shell or the interface, while more hydrophobic drugs are entrapped most likely in 
the inner core. The release rate of drug is a function of its localisation within the 
nanoparticles. The outer shell region of the nanoparticles is quite mobile, and drug 
release from this area is rapid. Therefore, the release of drug localised in the corona or 
at the interface is responsible for the ‘burst release’ (Teng et al., 1998). 
 
2.8.3 Physical state of the hydrophobic core 
 
The rate of drug release is also controlled by the state of the nanoparticles core (e.g 
solid or liquid-like) (Kwon et al., 1997). The physical state of the core under 
physiological conditions (37oC) is largely dependent upon the glass transition 
temperature of the core-forming block as well as the degree of its crystallinity (Allen et 
al., 1999a). According to Cowie (1994), the nanoparticles have a glassy core if the 
glass transition temperature of the core-shell nanoparticles is higher than that of the 
core-forming block; conversely, the nanoparticles have a liquid-like core. The lower 
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glass transition temperature is attributed to the plasticisation of the solvent or drug 
molecules incorporated. 
 
The design of polymeric nanoparticles with glassy cores would yield drug release in a 
sustained manner. Teng et al. (1998) reported that pyrene release from glassy cores 
formed from poly(styrene) and poly(tert-butyl acrylate) was well sustained. In contrast, 
pyrene was released too rapidly to be measured from the swollen cores of poly(2-
vinylpyridine), which were liquid-like under the experimental conditions. 
 
2.8.4 Length of the core-forming block 
 
The properties of the nanoparticles core, such as the core radius, also influence drug 
release rate, which is localised inside the hydrophobic core. Longer core-forming block 
produces larger core, resulting in slower drug release (Allen et al., 1999a). However, if 
the drug is located at the core-shell interface or in the outer shell, it does not have to 
diffuse through the core. In this case, drug release is not influenced by the core radius 
or length of the core-forming block. For example, Hruska et al. (1993) found that the 
exit rate coefficient for the fluorescent probe BAN was independent of the size of the 
micelle since it resides close to the core surface. 
 
2.8.5 Molecular volume of the drug 
 
The size or molecular volume of the drug affects its diffusion from the core-shell 
nanoparticles (Teng et al., 1998). Drugs with larger molecular volumes have a smaller 
diffusion coefficient, resulting in a decreased release rate. However, the release of 
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drugs localised at the surface of the nanoparticles should be independent of the 
molecular volume (Allen et al., 1999a). 
 
2.8.6 Physical state of the drug in the nanoparticles 
 
The physical state of the drug within the core-shell nanoparticles can have a significant 
effect on drug release kinetics. The incorporated drug may be either well solubilised or 
undissolved in the hydrophobic core. If the drug is molecularly dissolved within the 
core, it may act as a plasticiser and lower the glass transition temperature of the core-
forming block. This in turn may accelerate the release of the drug from the 
nanoparticles.  
 
On the other hand, if the drug is undissolved in the core, it may exist instead as a 
crystal within the nanoparticles core (Benoit et al., 1986; Donbrow, 1991). The present 
of the drug as a crystal may act as reinforcing filler. In particular, if strong interactions 
between the polymer and the surface of the crystallite are present, an increase in the 
glass transition temperature may occur. A sustained release of drug may be yielded 




Most of the polymeric core-shell nanoparticles designed was reported to be spherical 
(Gref et al., 1994; Jeong et al., 1998; Li and Kwon, 1999; Li and Kwon, 2000). 
However, morphologies other than spheres are of interest because of their different 
applications in drug delivery. For instance, rod-like core-shell nanoparticles have 
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different loading capacity and drug release kinetics compared to the spherical core-
shell nanoparticles. The rod-like nanoparticles may be the most useful in the 
preparation of aerosol formulations because they have been shown to be more suitable 
than spheres (Ding and Liu, 1998). A transfer to rod, vesicles, ellipsoid and lamellar 
core-shell nanoparticles may occur as the copolymer composition and concentration, 
type and concentration of added ions and the nature of the common solvent used in the 
preparation of core-shell nanoparticles are altered (Table 2.4). 
 
Table 2.4 Morphogenic factors that control the morphology of core-shell nanoparticles 
and examples of each (Adapted from Allen et al., 1999a) 
Morphogenic 
factors 



















2.0 w % 
2.6 w % 








Presence of added 
acid, base or salt 
PS-b-PAA 








Zhang et al., 
1996a 
Base PS-b-PAA 
410-b-13 (2 w %) 





Spheres (D = 38 nm)  
Spheres (D = 35 nm)  




410-b-25 (1 w %) 




Zhang et al., 
1996a 








Yu et al., 1997; 





 Literature Review 
 
 - 30 - 
2.9.1 Copolymer composition  
 
Changing the copolymer composition can have a significant effect on the degree of 
core-stretching and inter-shell interactions. The degree of stretching of the core-
forming blocks decreases when there is an increase in the length of the core and/or 
shell-forming blocks, while keeping the other block constant. For example, in spherical 
micelles containing a long poly(acrylic acid) (PAA) block and a polystyrene block of 
some particular length, when the length of the poly(acrylic acid) was decreased, the 
degree of core-stretching increased, and the morphology was changed to rod shape 
(Allen et al., 1999a). 
 
On other hand, an increase in the length of either block leads to an increase in the 
inter-shell chain repulsions (Allen et al., 1999a). For example, in spherical micelles 
formed from PS-b-PAA copolymers with a long PAA block, in which the aggregation 
number was restricted by inter-shell repulsion, as the PAA block length was decreased, 
the inter-shell repulsions became less important. Thus, the aggregation number was 
restricted by the degree of stretching of the core-forming blocks. Eventually, a further 
decrease in the length of the PAA block led to a change in morphology from spheres to 
rods and even to vesicles (Zhang and Eisenberg, 1996b). 
 
2.9.2 Copolymer concentration 
 
An increase in the copolymer concentration increases the aggregation number of the 
core-shell nanoparticles (Zhang and Eisenberg, 1997). The increased aggregation 
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number resulted in the production of rods and vesicles under the conditions that 
previously produced spheres and rods, respectively.  
 
2.9.3 Presence of added acid, base or salt 
 
The presence of ions influences the morphology by affecting the inter-shell chain 
interactions (Zhang et al., 1996a; Zhang and Eisenberg, 1996a). The addition of 
electrolytes to the solution of core-shell nanoparticles was found to either strengthen or 
weaken the inter-corona repulsive interactions, depending on the nature of the ions 
added. For example, in the PS-b-PAA solution (DMF/water), PAA is slightly ionised, 
therefore the addition of HCl protonates the ionic sites, resulting in a decrease in the 
inter-shell repulsions, which in turn caused a morphology change from spheres to rods 
or vesicles  (Zhang et al., 1996a). 
 
2.9.4 Organic solvent 
 
The choice of organic solvent has a profound effect on the morphology of 
nanoparticles (Allen et al., 1999a). It is difficult to predict the morphology when 
different organic solvents or precipitants are employed. However, an intermediate 
morphology can be obtained using a mixture of two organic solvents, in which the 
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2.10 Targeting 
 
The concept of selective delivery of drugs to specific physiological sites, organs, 
tissues or cells, where pharmacological activities of drugs are required, was first 
introduced by Erhlich (1906) in the early 20th century. He proposed the ‘magic bullet’, 
i.e. carriers with specific affinity for certain organs, tissues or cells for drug targeting. 
However, among different drug carriers, polymeric core-shell nanoparticles find the 
most practical applications in a variety of pharmaceutical fields, from oral delivery to 
sustained release and site-specific drug targeting (Jones and Leroux, 1999). This is 
owed to the structural similarity of polymeric core-shell nanoparticles to natural 
carriers, e.g. viruses and serum lipoproteins. 
 
Targeting the drug to the desired site of action would not only improve the therapeutic 
efficiency but also enable lower accumulation of the drug in healthy tissues, thus 
minimising unwanted toxic effects. For example, it was shown that adriamycin-loaded 
micelles accumulated much better in tumours than in non-target tissues (e.g. heart) 
(Kwon et al., 1994a). Polymeric core-shell nanoparticles are also associated with a 
lower toxicity, which allows for the administration of higher doses that are found to be 
toxic. For instance, the activity of DOX on tumours is limited by its toxicity, thus the 
maximum tolerated dose (MTD) is estimated to be 10 mg/kg. However, incorporation 
of DOX in PEO-b-P(Asp) micelles permitted the administration of DOX doses as high 
as 50 mg/kg (MTD) (Yokoyama et al., 1998b).  
 
Targeting can be divided into two categories, which are the passive and active 
targeting. 
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2.10.1 Passive targeting 
 
Passive targeting involves the random movement of the delivery system through the 
body. Passive targeted systems use natural flow in areas such as blood stream or 
gastrointestinal tract, and at a specific physiological site of uptake, the drug is released.  
The primary advantage of polymeric core-shell nanoparticles following intravenous 
administration is the ability to achieve a prolonged systemic circulation time in the 
bloodstream. They can effectively evade non-specific capture at the reticuloendothelial 
systems (RES) since the size of the core-shell nanoparticles (< 200 nm) is smaller than 
the threshold (approximately 200 nm) for the capture of RES. In addition, their 
hydrophilic shell can induce steric repulsive forces and stabilise the nanoparticles 
interface, preventing the adsorption of proteins and adhesion of cells that can cause 
recognition and uptake by the mononuclear phagocyte system (MPS).  
 
On the other hand, the nanoparticles are expected to show low renal clearance because 
their size is much larger than the pore size for renal filtration, unless the core-shell 
nanoparticles structure dissociates to unimers (Kwon et al., 1993b; Xu et al., 1991). 
Even if polymer molecular weight is lower than the critical molecular weight for renal 
filtration, they can also escape renal excretion because of the high molecular weight of 
nanoparticles (> 106 gmol-1) (Jones and Leroux, 1999). It was reported that intact core-
shell nanoparticles were recovered from plasma several hours after intravenous 
injection (Kwon et al., 1994a; Roland et al., 1992). 
 
The nanoscopic size of the core-shell nanoparticles is also advantageous for 
extravasation, which is an essential process for the carrier to reach the target tissues 
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such as solid tumours and sites of inflammation (Siegal et al., 1995; Yuan et al., 1994) 
that is located outside of the capillaries (Weinstein and van Osdol, 1992).  Due to its 
small size and highly hydrated as well as flexible shell, nanoparticles can slowly 
accumulate (so-called enhanced permeability and retention effect, EPR, also known as 
accumulation via an impaired filtration mechanism) in pathological sites with affected 
and leaky vasculature (e.g. tumours, inflammations and infected areas), improving the 
efficacy of drug and reducing unwanted side effects (Gabizon, 1995; Matsumura and 
Maeda, 1986; Maeda et al., 2000; Palmer et al., 1984). For example, micelles of PEO-
b-P(Asp)-DOX conjugates passively accumulated at solid tumours of mice with 
plasma levels higher than free DOX. After one day, the plasma levels of conjugate 
were about 10-fold higher than that of the drug itself (Kwon et al., 1994a). 
 
2.10.2 Active targeting 
 
Drug targeting could be further improved by utilising actively targeted drug delivery 
systems. The purpose of active targeting is to alter the natural distribution pattern of 
drugs to direct drugs to specific organs, and to control interactions with target sites. 
This can be achieved by binding pilot molecules such as antibodies (Kabanov et al., 
1989; Ulbrich et al., 2003) or sugar moieties (Cho et al., 1998; Yasugi et al., 1999) to 
the core-shell nanoparticles. Without creating any steric hindrances for the antibody, 
the antibody or its fragment can be chemically attached to an activated water-exposed 
free terminus of hydrophilic block of core-shell nanoparticles. Kabanov et al. (1989) 
reported that there was an increase in neuroleptic action and toxicity of haloperidol in 
the brain of mice for PEO-b-Poly(propylene oxide)-b-PEO micelles (Pluronic P-85) 
with murine polyclonal antibodies. 
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Another approach to achieving active targeting is to introduce a polymer sensitive to 
variation in temperature (Cammas et al., 1997; Chung et al., 1998) or pH (Meyer et al., 
1998; Taillefer et al., 2000). The development of thermo and/or pH sensitive polymeric 
core-shell nanoparticles has been pursued to enhance cellular interaction as well as 
release in specific sites. 
 
Many pathological processes in various tissues and organs are accompanied with local 
temperature increase (Helmlinger et al., 1997; Tannock and Rotin, 1989). Therefore 
thermo-response may be utilised to enhance drug release and/or vascular transport. An 
in vitro study on DOX-loaded PNIPAAm-b-poly(butylmethacrylate) (PBMA) micelles 
showed that below the LCST (33oC), the release of DOX from the micelles remained 
under 20% and the micelles formulation exhibited lower cytotoxicity than free DOX 
towards bovine aorta endothelial cells. However, at temperatures above the LCST, the 
activity of the micelles was greater than that of free DOX. Also, the release of DOX 
from the micelles reached 80% after 15 hours at 37 and 40oC (Jones and Leroux, 1999).  
 
The pH-sensitive core-shell nanoparticles could serve for the delivery of drugs to 
tumours, inflamed tissues or endosomal compartments since they are all associated 
with a lower pH value than normal tissues (Helmlinger et al., 1997; Tannock and Rotin, 
1989). They can disintegrate in such areas, and release the incorporated drug (Pratten 
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2.11  Research objective 
 
The main objective of this study is to investigate the potential application of two types 
of core-shell nanoparticles made from cholesteryl end-capped poly(N-
isopropylacrylamide-co-N,N-dimethylacrylamide) [P(NIPAAm-co-DMAAm)] and 
poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide-co-oleic acid) [P(NIPAAm-
co-DMAAm-co-OA)], respectively. Specifically, 
 
1. To investigate the possibility of using thermally responsive cholesteryl end-capped 
P(NIPAAm-co-DMAAm), and pH as well as thermally responsive P(NIPAAm-co-
DMAAm-co-OA) amphiphilic polymers for the entrapment of hydrophobic drugs, 
such as cyclosporin A (CyA) and indomethacin (IMC). 
 
2. To explore the influence of temperature, polymer structure and concentration, and 
drug molecular size as well as initial drug loading level on the encapsulation 
efficiency of drugs. 
 
3. To study the effect of temperature/pH or other possible parameters on in vitro 
release behaviours of drugs from the core-shell nanoparticles. 
 
 Materials and Methods 
 
 - 37 - 




Unless stated otherwise, all reagents and solvents were of commercial grade, and used 
as received. Cholesteryl end-capped poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide) [P(NIPAAm-co-DMAAm)] and poly(N-isopropylacrylamide-co-
N,N-dimethylacrylamide-co-oleic acid) [P(NIPAAm-co-DMAAm-co-OA)] were 
kindly provided by Dr. Liu Xue-Ming and Ms Wang Li-Shan, respectively. 
Indomethacin (IMC, Mw 358), cyclosporin A (CyA, Mw 1202), bovine serum albumin 
(BSA), and pyrene were purchased from Sigma, USA. Fetal bovine serum (FBS) was 
supplied from Invitrogen Corporation, UK. N,N-Dimethylformamide (DMF) was 
purchased from J.T. Baker (NJ, USA). Water was purified with Milli-Q® Ultrapure 





3.2.1 Characterisation of polymers 
3.2.1.1 Determination of composition 
 
The composition of polymers was determined by 400 Hz 1H NMR spectrometer 
(Bruker AVANCE 400). CDCl3 was used as the solvent. Chemical shifts were 
expressed in parts per million (δ) using residual protons in the indicated solvent as the 
internal standard.  
 
 Materials and Methods 
 
 - 38 - 
3.2.1.2 Determination of polymer molecular weight  
 
The molecular weight of polymers and their polydispersity were measured by a gel 
permeation chromatography (GPC) system consisting of a Waters 2690 separation 
module and a 410 RI detector (Waters, Milford, MA, USA) with HR 1E and HR 2E 
columns (Waters, Milford, MA, USA). Tetrahydrofuran (THF) (J.T. Baker, USA) was 
used as the mobile phase at a flow rate of 1.0 mL/min and polystyrenes (Polymer 
Laboratories Ltd, Amherst, MA 01002, USA) with various molecular weights were 
employed as calibration standards. About 10 mg of polymer was dissolved in 2 mL of 
THF and the solution was then filtered. Weight average molecular weights were 
calculated from a calibration curve using a series of polystyrene standards (Polymer 
Laboratories Inc., MA, USA) with molecular weights ranging from 1350 to 151700. 
 
3.2.1.3 Thermal degradation study  
 
Thermal degradation study of P(NIPAAm-co-DMAAm-co-OA) polymer was 
performed using a thermogravimetric analyser (TGA) (Perkin-Elmer TGA 7, USA) 
under nitrogen flow at 20 mL/min. The sample weight was around 4-5 mg, and it was 
heated from 50 to 800oC with a heating rate of 40oC/min. The temperature at 5 w % of 
polymer loss was considered to be the onset of polymer degradation. The temperature 
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3.2.2 Characterisation of drugs 
3.2.2.1 Thermal degradation study 
 
Thermal degradation study of IMC and CyA was performed using TGA as described 
above. 
 
3.2.2.2 Determination of IMC solubility 
 
The solubility of IMC was determined as described by Příborský et al. (1998). An 
excess amount of IMC was added to the phosphate buffer solution (PBS, pH 7.4), pH 6 
and pH 9 buffers, respectively. The solution was then vortexed and kept at certain 
temperatures for few hours. The solution was then centrifuged (5417R, Eppendorf, 
Germany) at 14000 rpm for 3 minutes, and filtered through a filter of 0.45 µm pore 
size to remove non-dissolved IMC. The concentration of IMC was determined by a 
UV-VIS microplate spectrophotometer (PowerWaveX, BIO-TEK Instruments, USA) at 
318 nm.  
 
3.2.3    Preparation of pH buffer solutions 
 
The buffer solutions of varying pH values were prepared according to buffer solutions 
reference (Dean, 1999). The ionic strength of the buffer solutions was adjusted to the 
ionic strength of PBS (0.18 M, pH 7.4) using sodium chloride (NaCl). The pH of the 
solution was measured at room temperature using a pH meter (744, Metrohm, 
Switzerland). Prior to the measurements, the pH meter was calibrated with proper 
standard buffer solutions. 
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3.2.4 Determination of LCST and phase transition pH  
 
The lower critical solution temperature (LCST) of the polymer solutions was 
determined by monitoring the optical transmittance as a function of temperature. 
Sample solutions of 5 mg/mL were determined at 500 nm using a Shimadzu UV-VIS 
spectrophotometer (Shimadzu UV-2501, Shimadzu, Japan). Sample cells were 
thermostated with a temperature controlled circular system (TCC-Controller, 
Shimadzu, Japan). The temperature was gradually increased with 0.3oC/min and 
0.1oC/min heating rate for cholesteryl end-capped P(NIPAAm-co-DMAAm) and 
P(NIPAAm-co-DMAAm-co-OA) polymers, respectively. The LCST of polymer 
solutions was determined at the temperature indicating 50% optical transmittance. The 
effects of pH and salts on the LCST were also investigated. The phase transition pH 
was further determined by observing the transmittance change of 5 mg/mL polymer 
solution as a function of pH at 31oC. The phase transition pH was determined at the pH 
showing an optical transmittance of 50%. 
 
3.2.5 Determination of CAC and polarity of the surroundings of pyrene by 
fluorescent probe techniques 
 
The critical association concentration (CAC) and the polarity of the nanoparticles core 
were determined by monitoring the changes in the fluorescence excitation and 
emission spectra of pyrene in polymer solutions (Chung et al., 2000). Fluorescence 
spectra were recorded using a LS50B Luminescence Spectrometer (Perkin Elmer, USA) 
as a function of polymer concentration and temperature (heating and cooling rate: 
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1oC/min). The temperature of samples was controlled with a thermostated circulating 
bath. Pyrene was used as a hydrophobic fluorescent probe for all measurements.  
 
The CAC values of the polymer in pH 4.0, 7.4 and 10.0 buffer solutions, as well as 
ultra pure water were determined. Pyrene solution in acetone (1.54 x 10-5 M, 400 µl) 
was added to 30 mL containers and the acetone was allowed to evaporate overnight. 
Hereafter, 10 mL of aqueous polymer solutions at a concentration ranging from 0.0005 
to 1.0 g/L were then added into the above containers containing the pyrene residue. All 
the aqueous polymer solutions contained final pyrene concentration of 6.17 x 10–7 M. 
The solutions were then allowed to equilibrate for 24 hours at 20oC. Both emission and 
excitation spectra were recorded.  
 
For cholesteryl end-capped P(NIPAAm-co-DMAAm) polymer, the emission spectra 
were recorded from 350 to 500 nm with an excitation wavelength of 340 nm. The 
excitation and emission bandwidths were set at 4.5 nm. The intensity (peak height) 
ratio (I1/I3) of the first band (374nm, I1) to the third band (391nm, I3) from the 
emission spectra was analysed as a function of polymer concentration. The CAC value 
was taken from the midpoint of the plot for I1/I3 changes.   
 
On the other hand, for P(NIPAAm-co-DMAAm-co-OA) polymer, the emission spectra 
were recorded from 360 to 420 nm with an excitation wavelength of 339 nm. As for 
the excitation spectra, the emission was carried out at 395 nm, and the excitation 
spectra were recorded from 300 to 360 nm. The excitation and emission bandwidths 
were set at 3 nm. The intensity ratio of peaks at 338 nm to those at 333 nm from the 
excitation spectra was plotted against the logarithm of polymer concentration. The 
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CAC values were obtained from the intersection of the extrapolations of the rapidly 
varying part of the plot and the nearly horizontal part at low polymer concentrations. 
To ascertain the polarity of the surroundings of pyrene, the intensity ratio of the first 
band to the third band (I1/I3) from pyrene emission spectra was analysed as a function 
of temperature. 
 
3.2.6 Preparation of core-shell nanoparticles 
 
Core-shell nanoparticles were prepared using the dialysis method. A total of 15 mg of 
polymer was dissolved in 5 mL of DMF. The polymer solutions were dialysed for 24 
hours against 500 mL of ultra pure water at different temperatures using cellulose 
dialysis membrane with the molecular weight cut-off of 2000 and 12000-14000 
(Sigma, USA) for cholesteryl end-capped P(NIPAAm-co-DMAAm) and P(NIPAAm-
co-DMAAm-co-OA) polymers, respectively. The water was replaced hourly for the 
first 7 hours. After dialysis, the solution remaining in the dialysis membrane was 
collected and centrifuged (5417R, Eppendorf, Germany) at 14000 rpm for 3 minutes to 
remove the aggregated nanoparticles. The supernatant, containing the core-shell 
nanoparticles, was filtered through a syringe filter of 0.45 µm pore size, and 
lyophilised by a freeze dryer (Labconco, USA) for 2 days to obtain dried nanoparticles. 
 
3.2.7 Incorporation of drug into core-shell nanoparticles 
 
CyA and IMC were loaded into the core-shell nanoparticles using a membrane dialysis 
method. Briefly, cholesteryl end-capped (0.5-3.0 mg/mL) P(NIPAAm-co-DMAAm) or 
P(NIPAAm-co-DMAAm-co-OA) (15.0 mg/mL) was dissolved in 5 mL of DMF, 
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followed by the addition of CyA (0.5-6.0 mg) or IMC (5-30 mg). The solutions were 
dialysed against ultra pure water at various temperatures (5, 10, 15 and 20oC) for 24 
hours. The water was replaced hourly for the first 7 hours. The solution was filtered 
using a filter of 0.45 µm pore size, and then analysed or lyophilised for 24 hours for 
further examination. In addition, P(NIPAAm-co-DMAAm-co-OA) solution was also 
dialysed against 0.02 M hydrochloride acid and 0.02 M sodium hydroxide solutions. 
 
3.2.8 Recovery of nanoparticles  
 
The lyophilised nanoparticles were weighed, and the nanoparticles recovery was 




veredreclesnanoparticofMasswwveryreclesNanopartic οο =         (3.1) 
 
3.2.9 Drug loading level and encapsulation efficiency 
3.2.9.1    CyA-loaded nanoparticles 
 
A fixed amount of CyA-loaded core-shell nanoparticles was first dissolved in 1 mL of 
chloroform, and 2mL of ether was then added drop-wise to precipitate the polymer. 
The suspension was centrifuged at 10000 rpm for 5 minutes. The supernatant was 
removed and dried. The sample was then reconstituted with an appropriate amount of 
mobile phase and analysed for CyA levels using high-performance liquid 
chromatography (HPLC). The HPLC system consisted of a Waters 2690 separation 
module and Waters 996 PDA detector (Waters Corporation, USA). A Waters 
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SymmetryShieldTM C8 4.6 x 15.0 cm column fitted with C8 pre-column was used. The 
mobile phase consisted of water and acetonitrile (15:85 in volume) with column and 
sample temperatures set at 50oC and 15oC, respectively. The detection wavelength was 
set at 210 nm. The retention time was 3.2 ± 0.1 min. A calibration curve was 
constructed to determine CyA concentration in the range from 1 to 20 ppm and the r2 
value was at least 0.999.  
 









edencapsulatdrugofMassefficiencyionEncapsulat =              (3.3) 
 
3.2.9.2    IMC-loaded nanoparticles 
 
The amount of IMC loaded in the nanoparticles was investigated using a UV-VIS 
microplate spectrophotometer (PowerWaveX, BIO-TEK Instruments, USA). To 
evaluate the loading amount of drugs, 1 mg of freeze-dried IMC-loaded nanoparticles 
was dissolved in 2 mL of methanol, and vigorously vortexed for an hour. The amount 
of IMC entrapped was determined by measuring the UV absorbance at 318 nm. Prior 
to this analysis, a calibration curve was constructed to determine the IMC 
concentration in the range from 2.5 to 70 ppm and the r2 value was at least 0.999.  
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The loading level and encapsulation efficiency were calculated from equations (3.2) 
and (3.3). 
 
3.2.10 Determination of DMF removal rate during the dialysis process 
 
The removal of DMF from the dialysis bag into the external aqueous phase was 
monitored at various temperatures (e.g. 5, 10, 15 and 20ºC). To simulate the 
fabrication process of drug-loaded core-shell nanoparticles, 5 mL of DMF was placed 
in a dialysis bag with a molecular weight cut-off of 2000 and immersed in 500 mL of 
ultra pure water at a fixed temperature. The external water was replaced hourly for the 
first 7 hours. At fixed time intervals, the solution in the dialysis bag was collected and 
analysed for DMF level by gas chromatography (GC, Perkin Elmer AutoSystem XL, 
Perkin Elmer, USA). The GC system was equipped with a flame ionisation detector 
(FID), and connected to an automatic liquid sample injector (Perkin Elmer 
Autosampler, Perkin Elmer, USA). A data processor (Turbochrom Navigator Version 
4.1) was employed for data acquisition and analysis of DMF levels. A 30 m long HP-1 
capillary GC column (J & W Scientific, USA, 0.25 mm in inner diameter and 0.25 µm 
in film thickness) was used. The injection port and detector were heated at 160oC and 
180oC, respectively. Helium, a carrier gas, was allowed to flow at a rate of 20 mL/min 
(90 psi). The supply of hydrogen gas and air to the detector was at 45 mL/min (60 psi) 
and 450 mL/min (60 psi), respectively. The sample was introduced to the column in a 
split mode with a ratio of 50:1 (He carrier gas and analyte). The column temperature 
was kept at 95oC for 5 minutes. The calibration curve was constructed using a series of 
DMF standards in a concentration ranging from 20 to 100% in volume (DMF/H2O) 
and the linearity was at least 0.99 (r2 = 0.995).  
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3.2.11 Characterisation of core-shell nanoparticles 
3.2.11.1 Morphology 
 
The surface morphology of the nanoparticles fabricated at different temperatures and 
pH was observed at 300 kV using a transmission electron microscope (TEM) (Philips 
CM300, Holland). A drop of the resultant nanoparticles solution containing 0.01 w/v 
% of phosphotungstic acid was placed on a copper grid coated with carbon film and 
dried at room temperature for overnight.  
 
3.2.11.2 Size analysis 
 
Average size and size distribution of nanoparticles were analysed by dynamic light 
scattering (DLS) (Coulter N4Plus, Coulter Corporation, UK) equipped with He-Ne 
laser beam at a wavelength of 633 nm. The intensity of the scattered light was detected 
at 90o to the incident beam. Measurements were obtained for nanoparticles fabricated 
under different conditions. The lyophilised nanoparticles were redispersed in water and 
vortexed for a few minutes. The samples were then filtered through a filter of 0.45 µm 
pore size and kept for 30 minutes at 20oC before measurements. 
 
In addition, changes in size of nanoparticles upon temperature cycles through the 
LCST were examined to investigate their thermo-responsive reversibility. For instance, 
after the first measurement at 20oC, the solution was heated to 40oC and incubated for 
30 minutes. Then, the solution was cooled back to 20oC. This heating and cooling were 
repeated for few cycles.  
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The size of nanoparticles was also measured as a function of temperature. Prior to the 
measurements, the solution was kept for 30 minutes at each temperature. The mean 
diameter ± S.D. of five determinations were obtained from unimodal analysis.  
 
3.2.11.3 Surface charge 
 
The zeta potential of P(NIPAAm-co-DMAAm-co-OA) nanoparticles was determined 
using a Zetasizer® 3000HSA (Malvern Instruments Ltd., Malvern, UK). The 
measurements of nanoparticles in ultra pure water were performed at different 
temperatures, ranging from 5 to 40oC. For each temperature, the mean value ± S.D. of 
five determinations was established.  
 
3.2.12 Fourier transformation infrared (FTIR) spectroscopy  
 
A FTIR spectrophotometer (Perkin Elmer Spectrum 2000, Perkin Elmer, USA) was 
employed to explore the nature of driving force for the formation of core-shell 
nanoparticles. A small amount of polymer or blank nanoparticles was mixed with 
potassium bromide (KBr) and pressed into disc for FTIR analysis. 
 
3.2.13 Determination of glass transition temperature (Tg) 
 
The glass transition temperatures of the polymer and core-shell nanoparticles were 
determined by modulated differential scanning calorimetry (MDSC) (TA 2920, 
Research Instruments Pte Ltd., USA) (Yamamoto et al., 2002; Zhang et al., 1996b) 
under nitrogen flow. About 5-6 mg of the samples were weighed into the aluminium 
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sample pans and then heated to 200oC at 10oC/min heating rate. The linear portion of 
the glass transition on the thermogram was extrapolated to the above and below glass 
transition, and the Tg was determined from the midpoint. The Tg values of polymers 
and nanoparticles were determined from the second heating run.  
 
3.2.14 Determination of melting temperatures (Tm) 
 
The melting temperatures of pure IMC and CyA, and those encapsulated in the 
nanoparticles were measured with MDSC (Jeong et al., 1998). The measurements were 
carried out using MDSC at temperatures ranging from 20 to 200oC with a heating rate 
of 5oC/min.  
 
3.2.15 In vitro drug release studies 
3.2.15.1 CyA-loaded nanoparticles 
 
The release of CyA from the cholesteryl end-capped P(NIPAAm-co-DMAAm) and 
P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles was determined by the 
dialysis method (Kim et al., 1998; Kim et al., 2000b; Kim et al., 2000c; La et al., 1996). 
About 5 mg of CyA-loaded nanoparticles was introduced into 1 mL of 0.18 M 
phosphate buffer solution (PBS, pH 7.4) in the cellulose dialysis membrane (molecular 
weight cut-off: 12000-14000, Sigma, USA). The membrane was then placed in 50 mL 
of PBS, which was incubated at 10, 20 and 40oC, respectively. At specific time 
intervals, the entire medium was removed and replaced with the same amount of fresh 
PBS. Subsequently, extraction of CyA was carried out by adding 5 mL of 
dichloromethane (DCM) into the collected medium. The mixture was then vigorously 
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vortexed for 3 minutes and left for phase separation. The extraction efficiency was 
determined to be more than 97%. The aqueous phase was drawn out carefully and the 
remaining organic phase was left to evaporate overnight. The dried sample was 
reconstituted with 2 mL of acetonitrile:water (85:15). The amount of CyA released into 
the medium was analysed with HPLC as described above. Release behaviours of CyA 
from P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles were investigated at 
31oC at pH 6 and 9. 
 
3.2.15.2 IMC-loaded nanoparticles 
 
Similarly, the release of IMC from the P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles was performed in PBS using the dialysis method (Kim et al., 2000b; Kim 
et al., 2000c; La et al., 1996; Kim et al., 1998). About 5 mg of IMC-loaded 
nanoparticles was introduced into 1 mL of PBS in cellulose dialysis membrane 
(molecular weight cut-off: 12000-14000, Sigma, USA). The membrane was then 
placed in 50 mL of the release medium, which was incubated at 20oC and 37oC. At 
predetermined time intervals, 1 mL aliquot of solution was withdrawn from the release 
medium. The samples were assayed using the UV-VIS microplate spectrophotometer 
at 318 nm. The solution taken as the sample was replaced with fresh medium. Release 
behaviours of IMC from the core-shell nanoparticles were also investigated at 31oC at 
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3.2.16 Evaluation of nanoparticles stability 
 
Besides the CAC and nanoparticles size, high in vivo stability of nanoparticles can also 
be weighed in terms of the interactions of core-shell nanoparticles with plasma 
components (serum proteins) (Chilkoti et al., 2002; Kwon et al., 1995; Lavasanifar et 
al., 2002). It is an important consideration especially for soluble thermosensitive 
carrier such as PNIPAAm, because such interactions can alter the LCST of the 
polymer, as well as promote recognition and uptake by the mononuclear phagocyte 
system (MPS). The interaction of P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles with serum proteins was studied by measuring the LCST (Meyer et al., 
2001) and size changes in the presence of bovine serum albumin (BSA) and fetal 
bovine serum (FBS). Prior to the LCST measurement, 0.5 mg/mL of polymer in 
different pH buffer solutions were incubated in 10 w/v % of BSA and 10 w/v % of 
FBS for 5 minutes, respectively. The optical transmittance was determined at 500 nm 
using the UV-VIS spectrophotometer. For the particle size analysis, the core-shell 
nanoparticles were suspended in 10 w/v % of BSA and 10 w/v % of FBS, respectively. 
The size distribution of core-shell nanoparticles was determined by DLS. The 
measurements were performed at 20oC by applying multimodal analysis. 
 
 Results and Discussion 
 
 - 51 - 
CHAPTER 4 RESULTS AND DISCUSSION 
 
4.1 Temperature-sensitive core-shell nanoparticles 
 
A thermally responsive cholesteryl end-capped poly (N-isopropylacrylamide-co-N,N-
dimethylacrylamide) [P(NIPAAm-co-DMAAm)] amphiphilic polymer (Figure 4.1) 
was designed and utilised to encapsulate hydrophobic drug within core-shell 
nanoparticles. Cholesterol was chosen as the hydrophobic segment because of its 
potential interaction with cholesterol receptors on cell surfaces (Alberts et al., 1989) 
and its well-known ability to drive the self-assembly of cholesteryl-containing 
materials (Goodby, 1998). The CAC and LCST values of core-shell nanoparticles were 
measured in various media, and the effects of salts and proteins were investigated. 
Model drug such as cyclosporin A (CyA) was encapsulated into the core-shell 
nanoparticles by a membrane dialysis method. The influence of temperature, polymer 
concentration, and initial drug loading level on the encapsulation efficiency of drugs 
was explored. The in vitro release of drug-loaded core-shell nanoparticles was also 































Figure 4.1 Chemical structure of cholesteryl end-capped P(NIPAAm-co-DMAAm) 
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4.1.1 Thermal analysis 
 
The FTIR spectra of the polymer and blank nanoparticles were compared (results not 
shown). No obvious differences were observed between the polymer and nanoparticles, 
indicating that the self-assembly of the core-shell nanoparticles was caused by physical 
interactions (e.g. hydrophobic interactions) of cholesterol segments, and there were no 
chemical interactions involved. This was further confirmed with DSC measurements. 
The Tg value of cholesteryl end-capped P(NIPAAm-co-DMAAm) was 128.5oC  
whereas its nanoparticles yielded a Tg value of 137.5oC.  This increase is due to the 
formation of a more orderly structure stabilised by intermolecular hydrophobic 
interactions, which required more energy to break down. 
 
4.1.2 LCST, CAC and their factors 
 
Figure 4.2 shows optical transmittance of core-shell nanoparticles made from 
cholesteryl end-capped P(NIPAAm-co-DMAAm) at various temperatures in different 
media. The LCST of the polymer in water was higher than that of PNIPAAm because 
of the hydrophilic contribution of DMAAm segments. The incorporation of 
hydrophilic segments shifts the phase transition point by increasing the water solubility 
of the polymer (Dong and Winnik, 1984). This phenomenon was consistent with what 
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Figure 4.2 Optical transmittance of cholesteryl end-capped P(NIPAAm-co-DMAAm) 
aqueous solution at various temperatures (polymer concentration: 5000 mg/L; 500 nm) 
 
PBS contains a large amount of salts including sodium chloride, which have a strong 
affinity with water molecules, reducing the number of free water molecules for 
polymer solubilisation. Thus, the phase transition was accelerated, and the LCST was 
reduced in the presence of salts. For instance, the LCST of cholesteryl end-capped 
P(NIPAAm-co-DMAAm) nanoparticles in PBS was 33.4°C but 37.0°C in water (Table 
4.1). Hydrophilic proteins like BSA also compete with the polymer chains for water 
molecules. Therefore, the presence of BSA or FBS (consisting of approximately 10% 
bovine albumin) further reduced the LCST. As protein concentration increased, LCST 
was further decreased (Table 4.1). For instance, the LCST of the nanoparticles in 
PBS/10% FBS, PBS/10% BSA and water/10% BSA was 33.4, 30.9 and 36.4°C, 
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Table 4.1 The LCST values of cholesteryl end-capped P(NIPAAm-co-DMAAm) in 





Medium Medium  Medium + 10% BSAb  Medium + 10% FBSc  
PBS (pH 7.4) 33.4 30.9 33.4 
Water 37.0 36.4 - 
a Determined at 500 nm.  
b Bovine serum albumin. 
c Fetal bovine serum. 
 
The CAC is an important parameter to characterise the behaviour of amphiphilic 
polymer in aqueous solutions. Above the CAC, amphiphilic polymer molecules can 
self-assemble into an ordered structure, in which a hydrophobic core is surrounded 
with a hydrophilic shell. The hydrophobic microenvironment of cholesteryl end-
capped P(NIPAAm-co-DMAAm) nanoparticles in aqueous solutions was investigated 
by fluorescence spectroscopy using pyrene as a probe. The ratio of I1 to I3 was 
monitored as a function of polymer concentration. Figure 4.3 shows a typical plot of 
I1/I3 for cholesteryl end-capped P(NIPAAm-co-DMAAm) polymer. A lower ratio is 
obtained when pyrene exists in more hydrophobic environment (Dong and Winnik, 
1984). This property of pyrene can be utilised to study core-shell nanoparticles 
formation and deformation. The CAC value was determined to be approximately 20 
mg/L for cholesteryl end-capped P(NIPAAm-co-DMAAm). The CAC value of the 
polymer in PBS (pH 7.4) was about 12 mg/L, which was lower than that in water. This 
is probably because the relative hydrophilicity of the polymer is lower in PBS.  
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Figure 4.3 I1/I3 changes as a function of cholesteryl end-capped P(NIPAAm-co-
DMAAm) polymer concentration 
 
4.1.3 Morphology and size distribution of the blank and drug-loaded core-
shell nanoparticles 
 
The size and morphology are important for evaluating the possibility of using core-
shell nanoparticles as a carrier for targeted drug delivery. Figure 4.4 shows TEM 
pictures of the blank and drug-loaded core-shell nanoparticles. Generally, the core-
shell nanoparticles formed were spherical in nature under the current fabrication 
conditions (e.g. polymer concentration: 0.3 w/v %, temperature: 10°C). The mean 
diameter of blank nanoparticles was about 50 nm. After loading with CyA, the mean 
diameter increased to more than 100 nm.  
 
 Results and Discussion 
 




Figure 4.4 TEM pictures of (a) blank and (b) CyA-loaded core-shell nanoparticles 
(fabrication temperature: 10°C, polymer concentration: 0.3 w/v %) 
 
 
Meanwhile, it was observed that upon heating of the nanoparticles solution to a 
temperature around the LCST, the size increased because of secondary aggregation 
(Figure 4.5). However, the aggregates re-dispersed and the size reduced to the original 










































































































Figure 4.5 Particle size changes when temperature cycles through the LCST                   
(polymer concentration: 0.3 w/v %) 
ba
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4.1.4  Drug encapsulation efficiency  
 
Figure 4.6 shows encapsulation efficiency of CyA-loaded cholesteryl end-capped 
P(NIPAAm-co-DMAAm) nanoparticles at different fabrication temperatures. The 
encapsulation efficiency and actual loading level of CyA were very low at room 
temperature. However, a reduced fabrication temperature yielded much greater 
encapsulation efficiency and loading level as well as bigger nanoparticles. For instance, 
the encapsulation efficiency of CyA at 5 and 20°C was 55 and 6.7%, respectively, and 
the actual loading level of CyA was 15.6 and 1.9 w/w %, respectively. The mean 
diameter of nanoparticles fabricated at 5 and 20°C was 193 and 41 nm, respectively. 
There were two possible factors that influenced drug encapsulation efficiency, 
including dissolution of CyA into the continuous phase during the dialysis process and 
precipitation of CyA upon solvent removal. CyA is a cyclic undecapeptide that 
exhibits unusual solubilisation behaviour in response to changes in temperature. The 
intramolecular H-bonds of CyA are strong at high temperatures. Thus, CyA adopts a 
conformation corresponding to an individual rather than solvated molecules. However, 
this conformation becomes weak as temperature decreases, resulting in higher water 
solubility (Loosli et al., 1985; Ismailos et al., 1991). For instance, the solubility of CyA 
in water increased approximately 15-fold when temperature was reduced from 37 to 
5oC (7.3 mg/L versus 101.5 mg/L). A study of CyA diffusion through the dialysis 
membrane with a molecular weight cut-off of 2000 was performed using a 40.0 ppm 
CyA aqueous solution at 10°C. The release rate of CyA from the dialysis bag was very 
low, which was less than 5% per hour. This is consistent with the finding of other 
researchers (Yang and Elmquist, 1996). The dissolution loss of CyA was hindered by 
the dialysis membrane barrier.  
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Figure 4.6 Effect of temperature on encapsulation efficiency of CyA-loaded 
cholesteryl end-capped P(NIPAAm-co-DMAAm) core-shell nanoparticles  
(polymer concentration: 0.3 w/v %; initial CyA loading: 28.5 w/w %)  
 
On the other hand, the solvent DMF, having much smaller molecular size, can diffuse 
through the dialysis membrane easily. An increased temperature yielded faster DMF 
removal as shown in Figure 4.7. This led to rapid precipitation of CyA before being 
entrapped into the core of nanoparticles. As observed during the experiments, the 
turbidity occurred at Hour 1 with the fabrication temperature of 15°C, but the solution 
was clear at 5°C during the whole dialysis process. During the dialysis process, core-
shell nanoparticles were formed as the solvent was removed and water content 
increased. Kohori et al. (2002) reported that the size of nanoparticles increased with 
increasing water content at the initial stage, but the nanoparticles shrank after reaching 
a maximum size value. It is believed that before the nascent nanoparticles started 
shrinking, there should be a liquid-state core, providing great flexibility for assembly 
of CyA molecules with the hydrophobic segments of polymer. With the progression of 
solvent removal, the core solidified, leading to difficulty in drug incorporation. Finally, 
 
 Results and Discussion 
 
 - 59 - 
strong hydrophobic interactions between hydrophobic segments of the nanoparticles 
and hydrophobic segments of CyA molecules resulted in a relatively stable structure 
within the solid-state core, and the incorporation of drug molecules stopped. The 
occurrence of shrinking suppressed drug incorporation. A reduced temperature yielded 
longer swollen time so that drug molecules had enough time to assemble into the core 
before precipitation. Therefore, fabrication temperature had dual effects on CyA 
encapsulation efficiency. A reduced fabrication temperature led to greater dissolution 
loss of the drug but less drug precipitation. From the fact that a reduced temperature 
yielded better CyA entrapment, precipitation of CyA upon rapid DMF removal at high 


































Figure 4.7 Effect of fabrication temperature on DMF removal  
 
The effects of polymer concentration and initial drug loading on CyA encapsulation 
efficiency were also investigated. An increase in polymer concentration yielded higher 
encapsulation efficiency and drug loading level (Figure 4.8). As reported by Liu et al. 
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(2003), higher polymer concentrations produced bigger nanoparticles. The number of 
polymer molecules in each nanoparticle was thus increased, providing a larger 
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Figure 4.8 Effect of polymer concentration on encapsulation efficiency of CyA-loaded 
cholesteryl end-capped P(NIPAAm-co-DMAAm) core-shell nanoparticles  
(initial CyA loading: 16.7 w/w %, temperature: 10°C) 
 
Table 4.2 shows the effect of initial drug loading at different temperatures. An increase 
in initial drug loading yielded lower encapsulation efficiency. The solvent removal 
might be promoted at higher drug contents because the interactions between the drug 
molecules and hydrophobic segments might lead to more free solvent molecules. Thus, 
the formation of solid-state core might be earlier at high drug contents, resulting in 
poor incorporation of drug molecules. Another possible reason is the precipitation of 
drug at high initial drug contents. At the initial stage of dialysis process, CyA was well 
dissolved in DMF. As water molecules penetrated into the dialysis membrane and 
DMF diffused into the external aqueous phase, the solubility of CyA was reduced in 
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the DMF-water mixture. After the core of nascent nanoparticles solidified, the residual 
CyA molecules that were not incorporated in the core-shell nanoparticles precipitated 
if the amount of residual CyA was greater than its solubility. As observed at 15°C, at 
the initial drug loading of 28.5 w/w %, the solution in the dialysis membrane appeared 
to be turbid during the first hour. However, at the initial loading of 16.7 w/w %, 
turbidity of the solution occurred after 4 hours dialysis and the extent of turbidity was 
much lower compared to that fabricated with the initial CyA loading of 28.5 w/w %. 
The similar phenomena were also observed for the core-shell nanoparticles fabricated 
at 10°C. 
 
Table 4.2 The effect of initial CyA loading on its encapsulation efficiency at various 
fabrication temperatures 
 
4.1.5  In vitro release studies 
 
Figure 4.9 shows the in vitro release profiles of CyA from the cholesteryl end-capped 
P(NIPAAm-co-DMAAm) core-shell nanoparticles at temperatures below and above 
the LCST. The physically entrapped CyA was gradually released over 24 hours, 
demonstrating a slow and sustained release characteristic. Higher amounts of CyA 
were released at 10 and 20oC than at 40oC, indicating that CyA release was faster at 

















15 0.3 28.5 6.5 23 +++ 
15 0.3 16.7 6.5 39 + 
10 0.3 28.5 12.0 42 ++ 
10 0.3 25.0 11.2 45 ++ 
10 0.3 16.7 11.0 66 + 
5 0.3 28.5 15.6 55 - 
5 0.3 10.2 6.3 62 - 
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temperature was raised above the LCST, there was a conformational change in the 
outer shell of the nanoparticles, in which the expanded form of the PNIPAAm was 
changed into a compact form. Hence, the diffusion of CyA from the core was restricted 
by the shrunken structure. This finding was consistent with the results of other 
researchers (Kim et al., 2000b; Kim et al., 2000c). The lower release rate of CyA at 
higher temperature could be also attributed to the unusual solubility behaviour of CyA 
in aqueous media, which was found to be inversely proportional to the temperature 
(Ismailos et al., 1991; Augustijns et al. 2000). Moreover, the tendency of CyA binding 






























Figure 4.9 Release of CyA from cholesteryl end-capped P(NIPAAm-co-DMAAm) 
core-shell nanoparticles in PBS (pH 7.4) at different temperatures  
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4.2   Temperature/pH-sensitive core-shell nanoparticles 
 
As introduced in Chapter 2, drug delivery systems capable of releasing active 
compounds in response to pH have been the most comprehensively studied due to the 
possible applications in targeted drug delivery. However, most of them are based on 
lipids. Very few studies have been reported for both temperature and pH-responsive 
core-shell nanoparticles (Taillefer et al., 2000).  
 
In this chapter, poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide-co-oleic acid) 
[P(NIPAAm-co-DMAAm-co-OA)] (Figure 4.10) was designed and utilised to form 
core-shell nanoparticles. In an aqueous medium, this polymer should form a core-shell 
structure, in which a pH-responsive hydrophobic core (oleic acid segment) is 
surrounded by the temperature-responsive outer shell [poly(NIPAAM-co-DMAAm)]. 
While maintaining the passive targeting ability, these temperature- and pH-sensitive 
nanoparticles possess a potential for active targeting by their reversible stimuli 
responsive character. The core-shell nanoparticles were characterised by size, CAC, 
LCST at different pH and morphology. The stability of the nanoparticles was 
examined in the presence of serum. 
 
Indomethacin (IMC) and cyclosporin A (CyA) are chosen as the model drugs. IMC, 
which is practically insoluble in water, is one of the most potent nonsteroidal anti-
inflammatory drugs for the treatment of conditions such as rheumatoid arthritis, 
ankylosing spondylitis, osteoarthritis and acute gouty arthritis (Figure 4.11). Its side 
effect, such as disturbance, ulceration and bleeding within the GI tract, are always 
found by oral administration. To avoid these adverse actions of IMC, administration by 
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injection has been extensively studied. CyA (Figure 4.12) is a cyclic undecapeptide 
and has been extensively used to prevent transplanted organ rejection and for the 
treatment of various autoimmune diseases. It is usually administered via oral and 
intravenous routes. Its major drawbacks are the broad toxicity profile including 
nephrotoxicity and hepatoxicity, and the low oral bioavailability because it is unstable 
and has a poor solubility in aqueous solution. The CyA or IMC-loaded P(NIPAAm-co-
DMAAm-co-OA) core-shell nanoparticles were fabricated by the dialysis membrane 
method. The effect of pH, temperature and initial drug loading on drug encapsulation 
efficiency was investigated. The release kinetics of drug was studied at different pH 
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Figure 4.10 Chemical structure of P(NIPAAm-co-DMAAm-co-OA) 
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Figure 4.12 Chemical structure of cyclosporin A (CyA) 
 
4.2.1 Characterisation of P(NIPAAm-co-DMAAm-co-OA) 
  
The compositions of P(NIPAAm-co-DMAAm-co-OA) were determined with 1H NMR 
spectrometer using CDCl3 as the solvent. Figure 4.13 shows the 1H NMR spectrum of 
the polymer. Signal a with two peaks overlapped was from CH2CHCONHCHMe2 in 
the NIPAAm moieties or CH2CHCONMe2 in the DMAAm moieties. Signals b, d, e 
and f were from CH2CHCONHCHMe2, CH2CHCONHCHMe2, CH2CHCONHCHMe2 
and CH2CHCONHCHMe2 in the NIPAAm moieties, respectively. Signals c and g 
were from CH2CHCONMe2 and CH2CHCONMe2 in the DMAAm moieties, 
respectively. Signal h was from the terminal Me group of oleic acid segment. From the 
integration ratio of the signals c and g to the signal e, the NIPAAm/DMAAm ratio was 
estimated to be 6:1. On the other hand, the NIPAAm/oleic acid ratio was estimated to 
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Figure 4.13 1H NMR spectrum of P(NIPAAm-co-DMAAm-co-OA) in CDCl3 
 
The molecular weights and polydispersity of the polymer were determined by GPC 
(relative to polystyrene standards). The weight average molecular weight of the 
polymer was 12.1k Da (Table 4.3).  
 
Table 4.3 Composition and weight average molecular weight of P(NIPAAm-co-
DMAAm-co-OA) 
Molar compositiond Mwa (Mw/Mnb)c 
NIPAAm DMAAm Oleic acid 
12.1k 1.8 6.0 1.0 0.2 
a Weight-averaged molecular weight. 
b Number-averaged molecular weight. 
c Polydispersity of the polymer. 
d The molar ratios of monomers were determined by NMR integration. 
 
The thermal properties of P(NIPAAm-co-DMAAm-co-OA) were examined by TGA 
measurements. Figure 4.14 shows the TGA thermogram of the polymer over the 
temperature range from 50 to 800oC. The thermogram under nitrogen flow shows a 


















CH CH ][ l
a b c 




 Results and Discussion 
 
 - 67 - 













































Onset of degradation 
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Figure 4.14 TGA thermogram of P(NIPAAm-co-DMAAm-co-OA) in N2 atmosphere 
 
4.2.2  Characterisation of drugs 
4.2.2.1  Thermal stability  
 
Figures 4.15 and 4.16 illustrate the thermogravimetric analysis (TGA) profiles of IMC 
and CyA, respectively. The thermograms for both IMC and CyA also show a single 
mass loss. The onset degradation temperature for IMC was 274.8oC. The degradation 
accelerated to a maximum rate when the temperature was raised to 340.9oC. CyA was 
stable up to 321.0oC and then rapidly degraded at around 404.0oC. By comparing the 
onset degradation temperature for both drugs, thermal stability of CyA was higher than 
that of IMC. This could be due to the larger structure of CyA and its higher molecular 
weight.  
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4.2.2.2  IMC solubility 
 
The aqueous solubility of a drug is important in determining its bioavailability. To 
elucidate the solubility of IMC in a range of isotonic pH buffer solutions, further 
experiments were carried out by adding excessive IMC into pH 6 to pH 9 buffer 
solutions, incubated at different temperatures. The solubility measurements are 
reported in Table 4.4. 
 
As expected, at a fixed incubation temperature (31oC), the solubility of IMC was 
higher at pH 9 than that at pH 6. IMC solubility showed a 5-fold increase at pH 9 
compared to pH 6. The improved solubility of IMC (pKa = 4.5) was influenced by the 
ionisation degree of the drug. Under alkaline condition, the carboxylic acid group of 
IMC was ionised, resulting in an increase of hydrogen bonding between the drug and 
water. Consequently, IMC solubilised to a greater extent in a basic medium. On the 
contrary, the low ionisation degree of IMC in pH 6 (> pKa) was expected to produce 
low drug dissolution.  
 
In addition, the solubility of IMC was determined in PBS (pH 7.4) at 20 and 37oC. An 
increase in the incubation temperature resulted in a corresponding increase in the 
solubility of IMC. From Table 4.4, IMC solubility at 37oC was estimated to be nearly 
2-fold greater than that at 20oC. This was attributed to the changes in the relative 
strengths of solvent-solvent, solvent-solute, and solute-solute interactions, in which the 
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Table 4.4 The solubility of IMC determined in different isotonic pH buffers 




9.0 31 2217.5 ± 4.4 
6.0 31   441.7 ± 6.4 
7.4 37   967.0 ± 6.8 
7.4 20   539.5 ± 5.5 
a Ionic strength is 0.18 M. 
b Mean ± S.D. of three determinations. 
 
4.2.3  LCST and phase transition pH of nanoparticles 
 
PNIPAAm is a thermoresponsive polymer that exhibits a lower critical solution 
temperature (LCST) of ca. 32oC (Ringsdorf et al., 1991). At temperatures below the 
LCST, the polymer is water-soluble but it precipitates when the temperature is raised 
above the LCST. To ascertain whether P(NIPAAm-co-DMAAm-co-OA) polymer 
exhibits a thermal response similar to the PNIPAAm homopolymer, the LCST 
transition of the polymer in water was characterised by monitoring the solution 
turbidity as a function of temperature. The LCST was determined by the temperature 
showing 50% transmittance at 500 nm. Figure 4.17 shows the optical transmittance of 
the aqueous solution of P(NIPAAm-co-DMAAm-co-OA) at various temperatures. 
 
The drop in transmittance as a function of temperature was quite broad. The LCST of 
the polymer in water was estimated to be 32.8oC, which was higher than that of 
PNIPAAm. Incorporation of DMAAm, which was a hydrophilic group, into the 
PNIPAAm chains strengthened the interactions between the polymer chains and water. 
Concurrently, there was an increase in enthalpy of hydrogen bonding between the 
polymer and water, thus stabilised the polymer dissolution. As a result, the phase 
transition phenomenon was slowed down, which subsequently raised the LCST.  
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In fact, incorporation of a terminal hydrophobic group had a reverse effect on the 
LCST. However, the thermoresponsive behaviour of core-shell nanoparticles 

























Figure 4.17 Transmittance changes as a function of temperature for solution of 
P(NIPAAm-co-DMAAm-co-OA) in water (polymer concentration: 5 mg/mL, 
absorbance at 500 nm) 
 
To elucidate the influence of pH on the LCST, the optical transmittance was measured 
for polymer in different pH buffer solutions at 500 nm, against temperatures. The 
polymer was soluble in aqueous buffers at room temperature, except for pH 4. Hence, 
prior to the measurements, the polymer solution that was prepared in pH 4, was filtered 
through a filter of 0.45 µm pore size. However, the solutions became turbid upon 
heating, indicating precipitation of the polymer. A series of plots of changes in 
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The drop in transmittance as a function of temperature was very sharp for solutions at 
higher pH values. It can be obviously seen that the LCST of the polymer was greatly 
influenced by the changes in pH. In an acidic buffer (pH 4.0 and pH 6.0), the LCST 
was determined to be 27.2 and 28.8oC, respectively. The LCST rose to 32.0oC at 
physiological pH. As the pH of the polymer solution was increased to 9, 10 and 11, the 
LCST of the polymer further increased to 33.5, 33.7 and 35.2oC, respectively. In 
solutions with pH value greater than pKa of 4.5, the carboxylic acid group of oleic acid 
segments was ionised, causing the polymer chains to interact more favourably with 
water. Increasing pH then promoted the ionisation degree of the carboxylic acid group. 
As a result, the enthalpy of hydrogen bonding between the polymer and water was 

























































Figure 4.18 Transmittance changes as a function of temperature for solutions of 
P(NIPAAm-co-DMAAm-co-OA) in various pH buffer solutions                           
(polymer concentration: 5 mg/mL, absorbance at 500 nm) 
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The phase transition pH of the nanoparticles was further determined by monitoring the 
transmittance change of the aqueous polymer solution as a function of pH at 500 nm. 
The pH showing an optical transmittance of 50% was estimated to be the pH of phase 
transition. Figure 4.19 shows the pH at which the phase transition occurred at 31oC in 
different isotonic aqueous buffers. The nanoparticles showed a phase transition around 
pH 6.25. The nanoparticles were water-soluble above the phase transition pH but 
precipitated when the pH was below the phase transition pH. The acidity of the 
P(NIPAAm-co-DMAAm-co-OA)  was due to the carboxylic acid group in the 
hydrophobic segment. At low pH, the carboxylic acid groups were protonated, thus the 
nanoparticles were insoluble in aqueous solution. However, as the pH of the polymer 
solution increased, the carboxylic acid groups were progressively deprotonated. This 
phenomenon will prolong until the polymer was fully ionised and subsequently soluble 

























Figure 4.19 Transmittance changes as a function of pH for solutions of P(NIPAAm-
co-DMAAm-co-OA) at 31oC (polymer concentration: 5 mg/mL, absorbance at 500 nm) 
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4.2.4  Formation of core-shell nanoparticles 
 
The formation of core-shell nanoparticles from the polymer was verified by the 
detection of critical association concentration (CAC) using a fluorescence technique. 
Fluorescence is a very sensitive technique and can detect the location of pyrene (e.g. in 
hydrophobic domains or in the aqueous solution). Pyrene was chosen as a fluorescent 
probe because its vibrational structure is sensitive to polarity and it produces distinct 
excimer fluorescence under conditions of sufficiently high concentration and mobility 
(Kalyanasundaram and Thomas, 1977). It is strongly hydrophobic and its solubility in 
water is very low. In the presence of core-shell nanoparticles, pyrene is solubilised into 
the inner core of the particles. As a result, significant changes in the spectroscopic 
properties are observed upon transfer of the pyrene from the aqueous environment to 
the non-polar environment of the inner core. Such changes can be observed from the 
emission and excitation spectra of pyrene.  
 
Both emission and excitation fluorescence spectra of pyrene are shown to depend on 
the nature of the solvent (Nakajima, 1971). However, the patterns of emission and 
excitation spectra recorded for pyrene in the aqueous solution of P(NIPAAm-co-
DMAAm-co-OA) were similar regardless of the solvent used. Figure 4.20 shows the 
emission spectra of pyrene, at fixed excitation wavelength of 339 nm, at various 
polymer concentrations. The fluorescence emission spectra of pyrene were affected by 
the polarity of its environment. An increase in the total fluorescence intensity and a 
change in the vibrational structure of monomer fluorescence were observed with 
increasing polymer concentrations, indicating the formation of core-shell nanoparticles. 
The excitation spectra of pyrene in the presence of P(NIPAAm-co-DMAAm-co-OA) 
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polymer at a fixed emission wavelength of 395 nm are shown in Figure 4.21. At low 
polymer concentrations, changes in the total fluorescence intensity and the shift of the 
(0, 0) band at 333 nm were insignificant. As the concentration of the polymer was 
increased, however, an increase in the total fluorescence intensity and a red shift of the 
(0, 0) band were clearly observed. Specifically, the (0, 0) band for pyrene, which is at 
333 nm in water, has been shown to shift to 338 nm upon addition of P(NIPAAm-co-
DMAAm-co-OA) polymer. The shift of the excitation peak demonstrated that the 
pyrene molecules gradually transferred to less polar microdomains of the interior of 


































Figure 4.20 Emission spectra of pyrene (6.17 x 10–7 M) at pH 10 in the presence of 
P(NIPAAm-co-DMAAm-co-OA) (excitation wavelength: 339 nm) 
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Figure 4.21 Excitation spectra of pyrene (6.17 x 10–7 M) at pH 10 in the presence of 
P(NIPAAm-co-DMAAm-co-OA) (emission wavelength: 395 nm) 
 
The CAC, which is the threshold concentration of self-assembly formation by intra- 
and/or intermolecular association, was determined from the change of the intensity 
ratio (I338/I333) of the pyrene in the presence of amphiphilic polymer. Figure 4.22 
illustrates the plot of the intensity ratio (I338/I333) from pyrene excitation spectra against 
the log C of P(NIPAAm-co-DMAAm-co-OA) polymer. CAC value was taken from 
the intersection of the tangent to the curve at the inflection with the horizontal tangent 
through the points at low polymer concentrations, as shown in Figure 4.22 (a). Below 
the CAC, the pyrene fluorescence spectrum exhibits a low value and mild slope of 
I338/I333. However, at the CAC, the curve shows a sharp increase in the I338/I333 ratio. 
From Figure 4.22 (a), the CAC in water was estimated to be 64.0 mg/L. Although the 
CAC of the P(NIPAAm-co-DMAAm-co-OA) in water was higher than that of the 
poly(ethylene oxide)-poly(β-benzyl L-aspartate) copolymer micelles (5.0-10.0 mg/L) 
(Kwon et al., 1993a), it was much lower than that of oligo(methyl methacrylate)-b-
poly(acrylic acid) copolymer micelles (100.0 mg/L) (Inoue et al., 1998).  
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To study the effect of pH on the CAC, the change of the intensity ratio (I338/I333) of 
pyrene in the presence of amphiphilic polymer, under acidic, physiological and basic 
conditions was evaluated [Figure 4.22 (b)]. The intensity ratio was relatively constant 
at low concentrations, and rapidly increased at high concentrations. The estimated 
CAC in pH 4.0, 7.4 and 10.0 was ca. 46.0, 64.0 and 81.0 mg/L, respectively. The core-
shell nanoparticles were formed at a higher concentration in basic environment, and 
with a lower CAC in acidic environment. The higher CAC value was attributed to the 
increase of hydrophilicity of the inner core. Increasing pH (> 4.5) promoted the 
ionisation of the carboxylic acid group. This inhibited the hydrophobic interactions, 
and thus a higher polymer concentration was required to form the hydrophobic core 
(Na et al., 2000). The results are similar to those reported by Han et al. (2003). The 
CAC of poly(L-lactide)/poly(ethylene glycol)-poly(sulfadimethoxine) increased with 
decreasing hydrophobic portion.  
 
In addition, the results obtained from this study also showed that the CAC was not 
affected by the presence of salts. It remained the same in both water and PBS (ca. 40 
mg/L). Zhang et al. (1996b) reported that the CAC of methoxy-poly(ethylene oxide)-b-
poly(D,L-lactide acid) was similar in water, 0.9% saline solution, and 5% dextrose 
solution. This is not surprising considering the non-ionic nature of the polymer. 
Another study also demonstrated that the CAC for poly(N-isopropylacrylamide-co-
methacrylic acid-co-octadecyl acrylate) in water and PBS was similar (Taillefer et al., 
2000). In the case of poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl 
acrylate) and P(NIPAAm-co-DMAAm-co-OA) polymers, increased ionisation of the 
polymer in PBS should enable the formation of core-shell nanoparticles at higher 
polymer concentrations. On the other hand, the presence of salt decreased the ability of 
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water as a solvent for polyelectrolytes, resulting in a lower CAC (Astafieva et al., 
1995). As a result, the effect of salt on CAC for these polymers in PBS was negligible.  
 




































Figure 4.22 Plot of intensity ratio I338/I333 from excitation spectra versus log C of 
P(NIPAAm-co-DMAAm-co-OA)in (a) ultra pure water and                                           
(b) different isotonic pH buffers  
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The change in the polarity of microenvironment of pyrene can be estimated from the 
specific intensity ratio of the (0, 0) band, I, to the (0, 2) band, III, in the fluorescence 
spectra of pyrene, which is known as the pyrene scale (Dong and Winnik, 1984). The 
ratio of the intensity of the I1/I3 is correlated to the dipolar and the dielectric constants 
of the solvent (Kalyanasundaram and Thomas, 1977). I1/I3 ratios were normally used 
to ascertain the location of pyrene. As reported by Gautier et al. (1999), a high I1/I3 
ratio indicated either that the hydrophobic character of the solubilisation regions is less 
pronounced (e.g. that they are less dense, or they are infiltrated with more water 
molecules), or pyrene partitioned towards the hydrophilic phase (e.g. expulsion from 
microdomains due to the structural deformation). This ratio is not preferentially used 
as a CAC determination procedure because it depends on the wavelength of excitation. 
When the excitation wavelength is 339 nm, the plot of the I1/I3 ratio is shifted in favour 
of pyrene in a hydrophobic environment. However, when the excitation wavelength is 
333 nm, it is strongly weighted toward pyrene in an aqueous medium. Figure 4.23 
shows micropolarity changes, as measured using polarity-sensitive pyrene, as a 
function of P(NIPAAm-co-DMAAm-co-OA) concentration. At low concentrations, 
the I1/I3 ratios were as high as ca. 1.45-1.55. As the polymer concentration increased, a 
sharp decrease in I1/I3 was observed. This indicates the partitioning of the hydrophobic 
pyrene probe into the hydrophobic microdomains, because of the formation of core-
shell nanoparticles.  
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Figure 4.23 Plot of intensity ratio I1/I3 from emission spectra versus log C of 
P(NIPAAm-co-DMAAm-co-OA) in different isotonic pH buffers 
 
4.2.5  Morphology of nanoparticles 
 
The morphology of P(NIPAAm-co-DMAAm-co-OA) and drug-loaded P(NIPAAm-co-
DMAAm-co-OA) core-shell nanoparticles was investigated at different temperatures 
and pH buffers with a transmission electron microscopes (TEM). The TEM images 
clearly indicated the presence of nanoparticles with nanoscopic dimensions as in a 
dehydrated state (Figure 4.24). The nanoparticles were spherical and discrete.  
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Figure 4.24 Transmission electron microscopes (TEM) photographs of (a) loaded 
nanoparticles (25.0 w/w % of IMC, water, 10oC); and unloaded nanoparticles at             
(b) 10oC (water), (c) 20oC (water), (d) pH 4.0 (10oC) and (e) pH 9.0 (10oC) 
 
4.2.6  Size and size distribution of nanoparticles 
 
The size of the nanoparticles is one of the major parameters that can affect their 
interactions with cells and distribution in the organs during their application as drug 
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nanoparticles prepared from the dialysis method were measured by a dynamic light 
scattering (DLS) equipped with He-Ne laser. Prior to the measurements, the 
lyophilised nanoparticles were redispersed in water, vortexed and then filtered through 
a filter of 0.45 µm pore size. Figure 4.25 illustrates the typical size distribution of 
P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles. It shows a bimodal pattern, 
a small portion at ca. 10 nm and a large portion at ca. 170-180 nm.  Therefore, they are 
considered to be an efficient drug carrier without scavenging by RES. The small 
particles should be due to drug and/or small polymer aggregates, which can be 
removed by filtration. 
 
 
Figure 4.25 Typical size distribution profile of P(NIPAAm-co-DMAAm-co-OA) core-
shell nanoparticles analysed by dynamic light scattering at 20oC 
 
Prior to getting the in-depth understandings of the influence of temperature and pH on 
the particle size, the effect of fabrication temperature was investigated. Unloaded 
nanoparticles were prepared using the dialysis method at 10 and 20oC, respectively. 
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Figure 4.26 Mean diameter of P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles prepared at different temperatures 
 
The thermal response behaviour of P(NIPAAm-co-DMAAm-co-OA) nanoparticles 
was further determined by studying the size change of the nanoparticles as a function 
of temperature. As shown in Figure 4.27, below 25oC, the particles showed a nearly 
constant size (ca. 170 nm). However, as the temperature was raised to 35oC, which was 
close to the LCST of nanoparticles in water, the size increased insignificantly. Further 
heating to 40oC (above the LCST) caused a markedly increase in size (Jeong et al., 
1999). The hydrodynamic size of the particles was speculated to remain constant while 
the aggregation number increased with temperature as a result of dehydration of the 
PNIPAAm chains in the outer shell. The increase in size was contributed by the 
aggregation at the temperature higher than the LCST.  
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Figure 4.27 Effect of temperature on the size of P(NIPAAm-co-DMAAm-co-OA) 
core-shell nanoparticles 
 
On the other hand, the thermoresponsive reversibility of P(NIPAAm-co-DMAAm-co-
OA) nanoparticles was evaluated in a repetitive heating and cooling cycle. In a 
hydrated state, the particle size was reversibly changed by temperature fluctuation 
from 20 to 40oC, as demonstrated in Figure 4.28. This might be caused by the thermal 
sensitivity of PNIPAAm in the outer shell of the nanoparticles. The aggregates formed 
upon heating redispersed to their initial structure upon cooling to the temperature 
below the LCST. However, the particles showed a smaller average diameter after each 
heating cycle. The possible reason is that some of large aggregates did not have ample 
time to redisperse to their hydrated structure, resulting in a lower polymer 
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Figure 4.28 Reversible temperature-responsive size change of P(NIPAAm-co-
DMAAm-co-OA) core-shell nanoparticles  
 
In addition to that, the pH-dependent behaviour of the polymeric nanoparticles 
prepared at 10oC was also examined by measuring the particle size as a function of pH. 
As shown in Figure 4.29, the mean diameter of the nanoparticles was about 40 nm at 
the pH where all carboxylic acid groups (pKa = 4.5) were in the acid form. However, 
with increasing pH to 9, the particles grew to ca. 130 nm because of a higher ionisation 
of the carboxylic acid group of oleic acid. The degree of ionisation of the carboxylic 
acid group controlled the balance between the repulsive and attractive intra- or inter-
molecular interactions (Gautier et al., 1999). Hence, a higher pH caused a decrease in 
the hydrophobicity of the core, leading to the swelling of the core.  
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Figure 4.29 Mean diameter of P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles as a function of pH 
 
4.2.7  Zeta potential of core-shell nanoparticles 
 
The surface charge of the nanoparticles was evaluated in water as a function of 
temperature by the zeta potential measurements. The zeta potential of the nanoparticles 
was -4 mV at 5oC and decreased in negativity to -20 mV at 40oC (Figure 4.30). Most 
of the carboxylic acid groups should be deprotonated in water. Therefore, the low 
surface negativity of the nanoparticles was due to the presence of ionised carboxylic 
acid groups of the oleic acid chains (Govender et al., 2000; Riley et al., 1999; Stolnik 
et al., 1995; Yamamoto et al, 1999). As the temperature was increased to be above the 
LCST, the collapsed PNIPAAm chains of the outer shell induced aggregation. 
Consequently, the particles presented higher negative charge on the surface at the 
temperature higher than the LCST because of the formation of larger particles. 
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Figure 4.30 Zeta potential of P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles in water as a function of temperature 
 
4.2.8  Drug incorporation into core-shell nanoparticles 
 
The possible application of P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles 
for drug delivery was evaluated by encapsulating hydrophobic drugs using the dialysis 
method. During this process, in the gradual decrease of organic solvent (DMF) in the 
dialysis bag, spontaneous hydrophobic association of oleic acid segments both with 
themselves and with hydrophobic drugs drive the formation of core-shell nanoparticles 
and drug incorporation. These interactions were significantly affected by the nature of 
drugs, fabrication temperature (Chung et al., 1999), dialysis medium (Yu et al., 1998), 
polymer concentration (Chung et al., 1999), initial drug loading (Allen et al., 2000; 
Chung et al., 1999; Kim et al., 1998; Kim et al., 1999; Kohori et al., 2002; Riley et al., 
1999; Shin et al., 1998; Yokoyama et al., 1998a), solvent exchange speed, organic 
solvent (Chung et al., 1999; Shin et al., 1998; Yokoyama et al., 1998a), and copolymer 
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composition (Govender et al., 2000; Kim et al., 1998; Nah et al., 1998; Yokoyama et 
al., 1998a). 
 
The incorporation of indomethacin (IMC) and cyclosporin A (CyA), respectively into 
the core-shell nanoparticles was carried out at 10oC. As shown in Table 4.5, the 
amount of CyA encapsulated was nearly 2-fold higher than that of IMC. The 
encapsulation efficiency of drug is dependent on the compatibility of drug and polymer, 
as well as the water-solubility of drug. Compared to IMC, both CyA and oleic acid 
molecules are more flexible. It might be easier for CyA and oleic acid segments self-
assemble into a compact core structure, resulting in higher encapsulation efficiency. 
On the other hand, IMC is more water soluble than CyA. During the fabrication 
process, dissolution loss of IMC might be higher than that of CyA, leading to lower 
encapsulation efficiency. 
 
The fabrication of core-shell nanoparticles was also performed at 20oC in order to 
investigate the effect of dialysis temperature. Similar trend for loading level and 
encapsulation efficiency was observed, in which 2-fold amount of CyA was 
encapsulated compared to IMC. However, it should be noted that higher incorporation 
was achieved at 10oC, for both IMC and CyA. As shown in Figure 4.7, at lower 
temperatures, the solvent exchange rate was lower, providing more time for the drug to 
be solubilised into the core of nanoparticles. In contrast, due to the rapid removal of 
solvent at higher temperatures, the hydrophobic drug precipitated out rather than being 
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Table 4.5 Loading level and encapsulation efficiency of indomethacin or cyclosporin 


















10 0.3 25.0 6.1 24.2 IMC 
20 0.3 25.0 3.7 14.7 
10 0.3 25.0 11.2 44.8 CyA 
20 0.3 25.0 7.3 29.2 
a 1w/v % = (1 g/100 ml) x 100%. 
b Calculated using equation (3.2). 
c Calculated using equation (3.3). 
 
To elucidate the effect of pH on drug incorporation, the dialysis was performed in 0.02 
M hydrochloride acid (HCl) and 0.02 M sodium hydroxide (NaOH) solutions, 
respectively at 10oC. The solubilisation of IMC and CyA occurred during self-
assembly of P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles as the alkaline 
or acidic aqueous solution replaced DMF. As expected, higher loading level and 
encapsulation efficiency were acquired as the pH of the dialysis medium decreased. 
This correlation is demonstrated in Figure 4.31. In highly basic environment, the 
carboxylic acid group of oleic acid was fully ionised. Hence, the increase of 
hydrophilicity of the oleic acid segment enhanced the solubility of the amphiphilic 
polymer in NaOH solution. As a result, only a small amount of core-shell 
nanoparticles was formed, leading to a drastic drop in drug incorporation. Nonetheless, 
the effect was more crucial when IMC was chosen as the model drug. The amount of 
IMC encapsulated decreased by ca. 96% when dialysed in NaOH solution. However, 
the incorporated CyA was only decreased by ca. 57% under similar conditions. This 
difference was due to the ionisation of the carboxylic acid group of IMC. Hence, a 
large quantity of IMC dissolved in NaOH solution rather than solubilised into the 
hydrophobic core of the nanoparticles. 
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Figure 4.31 Actual loading level and encapsulation efficiency of (a) indomethacin and 
(b) cyclosporin A in P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles at 
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4.2.9  Influence of initial drug loading on drug encapsulation 
 
The influence of initial loading of indomethacin on drug encapsulation was studied at 
10oC. Drug incorporation was performed by varying the amount of IMC fed. As 
demonstrated in Figure 4.32, an increase in initial loading from 25 to 67 w/w % led to 
an increase in encapsulation efficiency until a maximum value was reached. At higher 
initial loadings, there were a greater number of drug molecules available for 
entrapment into the nanoparticles. The entrapment of drug molecules made the core 
more flexible, resulting in greater encapsulation efficiency. However, there was only a 
small variation of encapsulation efficiency with wide range of initial drug loadings (ca. 
25 to 50 w/w %). This could be attributed to the decrease in nanoparticle recovery (ca. 
35.5 to 20 w/w %), which would lead to drug loss. When initial drug loading was 
increased to 57 w/w %, the encapsulation efficiency started to show a decreasing value. 
This indicated that there was a higher amount of IMC not incorporated into the 
nanoparticles (high drug wastage of ca. 70%) during the preparation process. Besides 
having a limited hydrophobic core, another reason for the decreasing drug entrapment 
with increasing initial drug loadings could be the low yield of nanoparticles. The 
nanoparticles recovery decreased sharply to 6-7 w/w % as the initial loading increased 
beyond 50 w/w %. A similar phenomenon was also observed by Kohori et al. (2002) 
for loading of adriamycin into poly(N-isopropylacrylamide-co-dimethylacrylamide)-b-
poly(D,L-lactide) nanoparticles.  
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Figure 4.32 Encapsulation efficiency of IMC in P(NIPAAm-co-DMAAm-co-OA) 
core-shell nanoparticles at different initial drug loadings (fabrication temperature: 10oC)  
 
4.2.10  Thermo-responsive inner core deformation 
 
Fluorescence spectroscopy using pyrene as a fluorescence probe was used to 
investigate the changes in the polarity and rigidity of the hydrophobic microdomains of 
core-shell nanoparticles. The intensity ratio (I1/I3) from pyrene emission spectra was 
monitored as a function of temperature above the critical association concentration 
(CAC). As described in previous paragraphs, a larger ratio indicates the higher polarity 
microenvironment around the pyrene probe. Pure PNIPAAm solutions showed an 
abrupt decrease in polarity when the temperature was raised through its LCST, 
indicating the transfer of pyrene into the precipitated polymer-rich phase (Chung et al., 
1997). In contrast, P(NIPAAm-co-DMAAm-co-OA) nanoparticles demonstrated an 
increase in polarity when heated above the LCST, as shown in Figure 4.33. The 
changes in polarity were also observed in various pH buffer solutions. Figure 4.34 (a), 
(b), (c) and (d) illustrates micropolarity changes as a function of temperature for 
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P(NIPAAm-co-DMAAm-co-OA) in pH 4.0, 6.0, 7.4 and 9.0 buffers, respectively. The 
nanoparticles showed a low and constant micropolarity below the LCST, regardless of 
the solvent used. Around the LCST, there was only a slight increase in polarity due to 
the collapse of shell. However, continuously heating to temperatures above the LCST 
caused a great rise in polarity around pyrene. Aggregation of collapsed PNIPAAm 
outer shells induced structural deformation of nanoparticles. This allowed pyrene to be 
exposed to the aqueous phase, resulting in an increase of pyrene polarity.  
 
In addition, the reversibility of the thermo-responsive nanoparticles was also examined 
by heating and cooling the solutions through the LCST (Figures 4.33 and 4.34). The 
pyrene polarity reduced to its initial level when the solutions were cooled to 
temperatures below the LCST, inferring that the deformed structure recovered back to 
the original structure upon rehydration of PNIPAAm chains. However, there was a 
small hysteresis around the LCST, which could be attributed to the delayed hydration 
of PNIPAAm chains upon cooling (Chung et al., 1997; Chung et al., 1999). 
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Temperature (oC)  
Figure 4.33 Plots of the ratio of intensities (I1/I3) of the vibrational bands in the pyrene 
fluorescence spectrum as a function of temperature for P(NIPAAm-co-DMAAm-co-
OA) in water, λex = 339 nm, [pyrene] = 6.17 x 10–7 M, 1oC/min, [polymer] = 1 g/L 
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Temperature (oC)  
Figure 4.34 Plots of the ratio of intensities (I1/I3) of the vibrational bands in the pyrene 
fluorescence spectrum as a function of temperature for P(NIPAAm-co-DMAAm-co-
OA) in (a) pH 4.0 (b) pH 6.0 (c) pH 7.4 and  (d) pH 9.0 buffers, λex = 339 nm,         
[pyrene] = 6.17 x 10–7 M, 1oC/min, [polymer] = 1 g/L 
 
Changes in the ratio of intensities (I1/I3) of the vibrational bands in the pyrene 
fluorescence spectrum for P(NIPAAm-co-DMAAm-co-OA) as a function of 
temperature were plotted in Figure 4.35 for easy comparison. At 31oC, the 
nanoparticles were stable at pH 7.4 and 9.0 but deformed at pH 4.0 and 6.0. This 
unique property can be utilised for intracellular drug delivery because the pH is around 
5-6 in endosomes.  
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Figure 4.35 Influence of pH on the intensity ratio (I1/I3) of the vibrational bands in the 
pyrene fluorescence spectrum as a function of temperature for P(NIPAAm-co-
DMAAm-co-OA), λex = 339 nm, [pyrene] = 6.17 x 10–7 M,  1oC/min,                   
[polymer] = 1 g/L 
 
4.2.11  Stability of core-shell nanoparticles in the presence of serum proteins 
 
Nanoparticles for intravenous administration are one of the approaches to the site-
specific delivery of drugs. Plasma protein adsorption is regarded as a key factor for the 
distribution of intravenously administered drug carriers and strongly depends on their 
surface characteristics (e.g. surface hydrophobicity or charge) (Gessner et al., 2002). 
Therefore, the aim in this study was to evaluate the stability of P(NIPAAm-co-
DMAAm-co-OA) core-shell nanoparticles in the presence of bovine serum albumin 
(BSA) and fetal bovine serum (FBS). Ten percent of BSA and FBS were chosen 
because these are the maximum possible concentration that can be found in the body. 
Two methods were chosen to determine the stability of the nanoparticles after 
incubation in BSA and FBS, including the size distribution and LCST measurements. 
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By using dynamic light scattering, the size distribution of the nanoparticles was 
measured as a function of time, in the presence of BSA and FBS. As illustrated in 
Figure 4.36 (i), BSA showed a bimodal size distribution with 78.0% of smaller 
particles (ca. 10 nm) and 22.0% of larger particles (180-220 nm). The same pattern 
was observed for the blank nanoparticles. However, the majority of the particles were 
in the range of 150-200 nm. After one-hour incubation, the size distribution for 
particles in the presence of BSA demonstrated a bimodal pattern with 78.0% of smaller 
particles (ca. 10 nm) and 22.0% of larger particles (180-220 nm). The content of larger 
particles decreased significantly probably because of dissociation of core-shell 
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Figure 4.36 Size distribution profiles of (A) bovine serum albumin (BSA) and (B) 
core-shell nanoparticles in presence of BSA at (i) 0 hr (ii) 1 hr (iii) 6 hrs and (iv) 24 hrs 
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Figure 4.37 demonstrated the size distribution of FBS and the nanoparticles in the 
presence of FBS. Both FBS and blank nanoparticles showed a unimodal size 
distribution. FBS was observed to form larger aggregates as the incubation time was 
prolonged. The aggregates were also found for the nanoparticles in the presence of 
FBS.  Then, because of further aggregation, the mean size increased. However, after 
six-hour incubation in FBS, although larger aggregates were formed with a longer 
incubation time, the amount of them decreased significantly (Figure 4.37 (B) (iii and 
iv)). Smaller particles (ca. 60-100 nm and 400-700 nm) that was not observed 
previously in the size distribution, started to appear, possibly indicating the 





 Results and Discussion 
 




Figure 4.37 Size distribution profiles of (a) fetal bovine serum (FBS) and (b) core-
shell nanoparticles in the presence of FBS at (i) 0 hr (ii) 1 hr (iii) 6 hrs and (iv) 24 hrs 
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Based on the above results, it seems that the dynamic light scattering measurement is 
not a suitable method to determine protein adsorption because both BSA and FBS tend 
to aggregate. Therefore, the stability of the nanoparticles was further investigated by 
measuring the LCST in presence of BSA and FBS since such interactions can alter the 
LCST of the particles. Table 4.6 showed that the LCST was only changed by less than 
2oC upon the addition of BSA and FBS, except for pH 11.0. However, under 
physiological condition (pH 7.4), BSA and FBS only lowered the LCST by 0.8 and 
0.2oC, respectively. This insignificant change proved that there were weak interactions 
between the protein and the particles.  
 
Table 4.6 The LCST values of P(NIPAAm-co-DMAAm-co-OA) nanoparticles 







Medium Medium + 10% BSA Medium + 10% FBS 
4.0 27.2 25.4 26.6 
6.0 28.8 26.9 27.4 
7.4 32.0 31.1 31.8 
9.0 33.5 32.5 33.0 
11.0 35.2 32.3 32.7 
a Ionic strength is 0.18 M. 
b Determined at 500 nm.  
 
4.2.12  Physical state of the hydrophobic core and encapsulated drug  
 
The physical state of the hydrophobic core of nanoparticles has a great influence on the 
rate of drug release (Allen et al., 1999a). The relative fluidity of the core was studied 
by measuring the glass transition temperature (Tg) of the polymer and nanoparticles 
using modulated differential scanning calorimetry (MDSC) (Burt et al., 1999). As 
shown in Figure 4.38, the Tg of polymer and nanoparticles were 130.6 and 128.4oC, 
respectively, indicating that the nanoparticles were in a glassy state at room 
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temperature. The lower glass transition temperature of nanoparticles was due to the 
plasticisation of water molecules in the core. This phenomenon was also observed for 
the micelles system developed from methoxy-ended PEG-b-PDLLA (Yamamoto et al., 
2002). Further decrease in Tg was observed when the hydrophobic drugs were 
incorporated into the nanoparticles (Table 4.7). The molecularly dispersed drug within 
the core was acting as a plasticiser and thus, lowered the glass transition temperature of 






























































Figure 4.38 DSC thermograms of P(NIPAAm-co-DMAAm-co-OA) polymer and 
core-shell nanoparticles 
 
Table 4.7 Effect of loading level on glass transition temperature of P(NIPAAm-co-
DMAAm-co-OA) core-shell nanoparticles containing IMC 
Initial loading 
(w/w %) 




25.0 6.1 125.7 
50.0 15.6 117.9 
66.7 18.3 118.0 
a Calculated using equation (3.2). 
b Glass transition temperature measured by MDSC. 
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Besides the physical state of the core, the physical state of incorporated drugs can also 
have a significant effect on the release kinetics since they can either exist as a crystal 
or disperse molecularly inside the core (Allen et al., 1999a). Figure 4.39 shows a sharp 
melting peak of indomethacin (IMC) at 161.8oC, signifying that IMC is a crystal at 
room temperature. However, no melting peak was observed when IMC was 
incorporated into the nanoparticles. This result indicated that IMC was molecularly 
dispersed within the core. Similar finding was observed for CyA (Figure 4.40). Naked 
CyA showed a melting peak at 127.5oC. After incorporated into the nanoparticles, the 







































































































Heat flow of Indomethacin

Heat flow of nanoparticles
Reversible heat flow of nanoparticles
Non reversible heat flow of nanoparticlesEndo
Melting temperature = 
161.8oCNo melting peak observed for drug-
loaded nanoparticles
Figure 4.39 DSC thermograms of P(NIPAAm-co-DMAAm-co-OA) polymer and 
IMC-loaded P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles                     
(actual drug loading: 6.1 w/w %) 
  
 
 Results and Discussion 
 





































































































































































Heat flow of Cyclosporin A

Heat flow of nanoparticles
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Melting temperature = 127.5oC No melting peak observed for drug-
loaded nanoparticles
 
Figure 4.40 DSC thermograms of P(NIPAAm-co-DMAAm-co-OA) polymer and 
CyA-loaded P(NIPAAm-co-DMAAm-co-OA) core-shell nanoparticles                      
(actual drug loading: 11.2 w/w %) 
 
Nonetheless, when the actual loading of IMC was increased to 18.3 w/w %, two 
crystalline peaks (158.4 and 164.8°C) were observed in the DSC thermogram of 
nanoparticles (Figure 4.41), indicating the drug existed as crystals in the core. This 
result was supported by studies done by Gref et al. (1994) and Jeong et al. (1998).  
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164.8oC
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Figure 4.41 DSC thermograms of P(NIPAAm-co-DMAAm-co-OA) polymer and 
IMC-loaded core-shell P(NIPAAm-co-DMAAm-co-OA) nanoparticles                       
(actual drug loading: 18.3 w/w %) 
 
4.2.13  Drug release study 
 
The in vitro release kinetics of indomethacin (IMC) and cyclosporin A (CyA) from the 
nanoparticles was investigated. Figure 4.42 shows the release profiles of IMC at 37 
and 20oC. IMC release was accelerated upon heating through the LCST, while the 
release was suppressed below the LCST. This was demonstrated in the release for the 
first 10 mins, where the amount of IMC released at 37oC was ca. 40 w/w %, which was 
2-fold higher than that at 20oC. The accelerated IMC release was in correlation with 
temperature-induced inner core structural deformation sensed by pyrene, as reported in 
previous paragraph. However, despite having a stable structure below the LCST, the 
particles were shown to exhibit an initial burst (ca. 60 w/w %) after an hour release. 
This is probably because of high water solubility of IMC in PBS (pH 7.4) and flexible 
core of nanoparticles.    
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Figure 4.42 Release of IMC from P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles in PBS (pH 7.4) at 37 and 20oC (actual drug loading: 6.1 w/w %) 
 
Figure 4.43 shows the release profiles of CyA from the nanoparticles at 20 and 37oC. 
Compared to IMC, CyA release was slower and more sustained probably because of its 
lower water-solubility and more stable core stemming from better compatibility 
between CyA and the core. A higher amount of CyA was released at 20oC than at 37oC. 
This could be ascribed to the unusual solubility behaviour of CyA in aqueous media. 
The solubility of CyA was found to be inversely proportional to temperature 
(Augustijns et al. 2000; Ismailos et al., 1991; Loosli et al., 1985). The higher the 
temperature, the lower is the solubility. Hence, at 37oC, upon the burst release of CyA 
from the deformed nanoparticles, CyA immediately precipitated. On the contrary, at 
the lower temperature, CyA slowly diffused out from the nanoparticles but only in a 
small amount because of the stable structure of the core.  
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Figure 4.43 Release of CyA from P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles in PBS (pH 7.4) at 37 and 20oC (actual drug loading: 11.2 w/w %) 
 
The release kinetics of IMC and CyA was further studied at different pH. Figure 4.44 
illustrates the release profiles of IMC at pH 9 and pH 6. The results revealed that the 
release of IMC was higher in the basic environment. Similar results were obtained in 
studies done by La et al. (1996). Under the basic condition (pH 9), the carboxylic acid 
group (pKa = 4.5) of IMC and oleic acid core were ionised, causing both of them to 
interact more favourably with water. As a result, the fluidity of the inner core increased 
and the hydrophobic interactions between the drug and core was reduced, thus 
accelerated the diffusion of IMC out of the ionised core.  Conversely, the release was 
lower in acidic condition despite having deformed nanoparticles (Figure 4.44). The 
low ionisation degree of IMC in pH 6 was expected to produce low drug dissolution, 
which was 5-fold lower than in pH 9 (Table 4.4). Hence, upon the burst release of IMC 
from the deformed nanoparticles, a portion of IMC precipitated and the rest diffused 
out into the release medium. 
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Figure 4.44 Release of IMC from P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles at 31oC at pH 9 and pH 6 (ionic strength: 0.18 M,                                  
actual drug loading: 6.1 w/w %) 
 
Ismailos et al. (1991) reported that the solubility of CyA was not affected by pH. As 
shown in Figure 4.45, the difference in CyA release between 20°C and 37°C was not 
significant because of the low water solubility of CyA. Since the LCST of the 
nanoparticles at pH 6 was lower than 31°C, the structure of nanoparticles was 
deformed upon putting into the in vitro medium. Subsequently, it precipitated after 
released from the core because of its low solubility, promoting aggregation between 
the nanoparticles and thus reducing surface area for CyA dissolution.  
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Figure 4.45 Release of CyA from P(NIPAAm-co-DMAAm-co-OA) core-shell 
nanoparticles at 31oC at pH 9 and pH 6 (ionic strength: 0.18 M,                                    
actual drug loading: 11.2 w/w %) 
 
4.2.14  Influence of drug loading content on release behaviours 
 
The effect of loading content on drug release kinetics was also explored by performing 
the in vitro release of IMC from nanoparticles with actual loading levels of 6.6 w/w % 
and 18.3 w/w %. As shown in Figure 4.46, an increase in drug loading level resulted in 
a slower release of IMC. This finding was consistent with the results of other 
researchers (Na et al., 2000; Gref et al., 1994; Jeong et al., 1998; Kim et al., 1999; Nah 
et al., 1998; Kim et al., 1998). It is possibly due to the physical state of the drug in the 
nanoparticles. As reported in previous paragraphs, IMC existed as crystals at the high 
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Figure 4.46 Release of IMC from P(NIPAAm-co-DMAAm-co-OA) core-shell 
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CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Conclusions  
 
Temperature-sensitive core-shell nanoparticles 
A new type of thermally responsive core-shell nanoparticles were successfully formed 
using cholesteryl end-capped P(NIPAAm-co-DMAAm) polymer. The core-shell 
nanoparticles were spherical and had a size of less than 100 nm in diameter. The 
amphiphilic polymer possessed a low CAC value, which was 20 mg/L. The CAC value 
was reduced in PBS. The LCST value of core-shell nanoparticles was lower in PBS 
(pH 7.4) than that in ultra pure water. The presence of serum albumin further reduced 
the LCST value. This core-shell nanoparticles system provided great capacity for 
loading of hydrophobic drug. Although there were a number of factors that influence 
drug encapsulation efficiency, drug precipitation was the dominant factor. Drug 
precipitation caused by rapid solvent removal at high temperatures and high initial 
drug contents led to low drug encapsulation efficiency. However, low fabrication 
temperature yielded a longer swollen phase, resulting in better drug entrapment. It was 
demonstrated that CyA release from the cholesteryl end-capped P(NIPAAm-co-
DMAAm) core-shell nanoparticles was faster at a temperature below the LCST. The 
core-shell nanoparticles system developed would make an important carrier for 
targeted delivery of hydrophobic drugs. 
  
Temperature/pH-sensitive core-shell nanoparticles 
Novel temperature and pH responsive core-shell nanoparticles, which can solubilise 
poorly water-soluble drugs, were successfully synthesised using P(NIPAAm-co-
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DMAAm-co-OA). The nanoparticles had a small size (less than 200 nm), low CAC 
(64 mg/L in water) and a good stability in the presence of serum proteins. The 
nanoparticles demonstrated reversibility of thermoresponsive aggregation/dispersion 
and deformation/reformation of structure in heating/cooling thermal cycles through the 
LCST. The drug entrapment efficiencies were shown to be dependent on temperature, 
pH and initial drug loading. The release behaviours of IMC and CyA from the 
nanoparticles were affected by pH, temperature and drug loading. The IMC-loaded 
nanoparticles exhibited rapid release while the CyA-loaded nanoparticles showed 
significant slow and sustained release characteristics. The release rate of IMC was 
increased by increasing pH and temperature but decreased in higher drug loading 
levels. On the other hand, higher CyA release rate was obtained at a lower temperature. 
The physical state of the drug and core had a great influence on the release behaviour 
of drugs from the nanoparticles. These nanoparticles have shown potential for drug 
targeting in both passive and active manner, enhancing site-specific drug accumulation 
and release induced by external pH and temperature stimuli. 
 
In conclusion, a new type of stimuli-sensitive core-shell nanoparticles based on 
thermally responsive cholesteryl end-capped poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide), as well as pH and thermally responsive poly(N-
isopropylacrylamide-co-N,N-dimethylacrylamide-co-oleic acid) amphiphilic polymers 
were successfully designed and utilised to encapsulate cyclosporin A (CyA) and/or 
indomethacin (IMC). Coupling with the EPR effect, the thermally and/or pH 
responsive core-shell nanoparticles systems may provide a good approach to targeting 
drugs to tumour and inflamed tissues.   
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5.2 Recommendations  
 
The ultimate goal of drug delivery systems capable of releasing hydrophobic drugs in 
response to temperature and/or pH is to provide higher drug release at low pH and high 
temperatures above the LCST, since tumours, inflamed tissues or endosomal 
compartments are often associated with lower pH and/or higher temperatures than 
normal tissues. Therefore, suitable drugs, whose water solubility is not sensitive to 
temperature and pH, should be chosen to study drug release kinetics. 
 
It is of primary importance to determine the core radius of the core-shell nanoparticles, 
viscosity of the inner core, and changes of pyrene fluorescence lifetimes with 
temperature to provide more detailed information on the effects of pH, polymer 
concentration and core-forming blocks on drug entrapment and release kinetics, 
physical state of the inner core, and the actual location of pyrene when the temperature 
is altered. 
 
Finally, it is also of interest to determine the cytotoxicity and biocompatibility of the 
polymers, plasma clearance and biodistribution of the core-shell nanoparticles, and the 
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Figure A.1 HPLC chromatogram of a CyA standard solution (Concentration: 30 ppm) 
 
 
Figure A.2 GC gaschromatogram of a DMF standard solution (Concentration: 30 ppm) 
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Figure A.3 GPC chromatogram of P(NIPAAm-co-DMAAm-co-OA) in THF 
 
 
 
 
